



**Kingdom of Saudi Arabia
Saudi Health Council
Saudi Cancer Registry**

Cancer Incidence Report Saudi Arabia 2012

An electronic version of the report is available at:

www.chs.gov.sa

Prepared by

Mrs. Wafa Abdullah Al-Zahrani
Mr. Zeyad Saeed Al-Shahrani
Mrs. Amal Nasser Al.-Madouj
Mr. Mohammed Saleh Hayder
Ms. Mona Mohammed Al-Shridah
Ms. Tahani Hussain Al-Shumrani

Reviewed by

Dr. Ali Saeed Al-Zahrani
Dr. Hind Mohammed Al-Mutlaq
Dr. Amer Naeem Radwi
Dr. Shouki Mohammed Bazarbashi

The SCR Scientific Committee Members

Dr. Ali Saeed Al-Zahrani	(Chairman)
Dr. Hind Mohammed Al-Mutlaq	(The Acting Director of SCR)
Dr. Mushabab Ali Asiri	(Regional Director of Central Region)
Dr. Hassnah Ali Al-Ghamdi	(Regional Director of Western Region)
Dr. Amal Mohammed Al-Behani	(Regional Director of Madinah and Northern Region)
Dr. Abdrrhman Ali Al-Shehri	(Regional Director of the Southern Region)
Prof. Hassan Yousef Al-Idrisi	(Regional Director of the Eastern Region)
Dr. Mohammed Yahya Saeedi	(Ministry of Health)
Dr. Amer Naeem Radwi	(Health Affairs- Ministry of National Guard)
Dr. Abdulaziz Saleh Abahussin	(Medical Services- Security Forces)
Dr. Ali Matar Al-Zahrani	(Medical Services- Military Forces)
Dr. Shouki Mohammed Bazarbshi	(KFSH & RC)
Dr. Abduziz Abdullah Al-Saif	(Ministry of Education, KSU)
Dr. Abdulrahem Toran Gari	(Private Hospital)



ISSN: 1658 - 0559

Foreword

I am very glad to share with you the Annual Cancer Incidence Report for 2012. This remarkable effort of Saudi Cancer Registry's team (SCR) is commendable. The hard work of the management of SCR to publish the annual report and their dedication to complete the report of 2012 before the end of 2015 as targeted was a major challenge. The role of the scientific team who took upon their shoulders the preparation of the report from a technical perspective following all stages of processing the report under the supervision of Dr. Ali Al-Zahrani, Chairman of the Scientific Committee of SCR is worth appreciation. Saudi Cancer incidence reports since 1994 contributed in supporting the fight against cancer through genuine scaling of its epidemiology and by providing those responsible for cancer control and prevention programs with accurate and detailed data that shows the real situation of cancer in the kingdom and identifies the most prevalent types of cancer according to demographics and geographical distribution. The reports help decision makers in planning to develop new cancer treatment and prevention centers, scientific research and conferences held in different regions of the country which supports the health strategies and objectives set by the Saudi Health Council.

It is worth mentioning that SCR. is targeting 2016 to minimize the period between the date of release of the annual report and the year the report covered from four to two years. This will be achieved by collaboration of tumor registrars, administrators, registry's director and the Scientific Committee. We hope that this will give more reliability to the registry to make decisions based on the latest information about the incidence of cancer in the Kingdom. The Saudi Health Council as it releases this report appreciates the contribution of health sectors and other relevant sectors.

The development in the health services in our beloved country is due to the blessings of the all mighty Allah and the support of our government under the leadership of the Custodian of the Two Holy Mosques and the Crown Prince and the Crown to the Crown Prince –May Allah protect them- who save no effort to provide the best health services to comfort the citizens of Saudi Arabia.

General Secretary, Saudi Health Council

Dr. Yagob Al-Mazrou

Introduction

This is the sixteenth incidence report published by the Saudi Cancer Registry. Previous publications include the Incidence Reports for the years 1994 - 1996 , 1997 - 1998 , 1999 - 2000 and yearly until 2011.

The structure of this report can be outlined as follows:

Part I-Materials and Methods

This part of the report contains information about the background of the Saudi Cancer Registry and methods used in collecting and analyzing the data. We present the basics of coding and classification of tumor topography, morphology and extent of disease at the time of diagnosis. Also we describe the software programs we have used to analyze the data.

Part II-Overview of Cancer Incidence

Part II contains figures and tables that show overall cancer incidence in Saudi Arabia for the year 2012. We present these figures and tables mainly by sex and in certain areas we have it analyzed by different age groups. There are bar charts representing the age distribution of cancer incidence for the year 2012 among Saudis by sex and age groups. We present incidence and morphology tables for the most common types of cancers among adults and children. In addition, tables, list the total number of cases, the Age-Standardized Incidence Rate (ASR) per 100,000 population, Crude Incidence Rate (CIR) and Cumulative rates by primary site and sex. Separate bar charts depict the most common types of cancer, by sex.

Part III- Cancer Incidence for Most Common Sites 2012

In this part the incidence of the most common cancers among Saudi males and females are outlined. A standardized layout presents data for all patients and for both sexes where applicable. For each selected site the number and the percentage of all newly diagnosed cases for the year 2012, the ASR for each sex and the specific cancer rank for both sexes are presented. In addition, ASR for the specified cancer among Saudis is compared with ASR among other populations from selected countries.

Part IV-Cancer Incidence among Non-Saudis

This part presents the incidence of cancer cases among Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in Saudi Arabia in which a large part of the population, particularly among males, falls in the 25 - 44 age groups.

Part V-Incidence Tables

Part V contains the following detailed tables for all newly diagnosed cancer types among Saudis and Non-Saudis for 2012.

- Distribution of cancer cases among Saudis by age group and sex.
- Distribution of cancer cases among Non- Saudis by age group and sex.
- Cancer Incidence (per 100,000 populations) among Saudis by age group and sex.
- Cancer Incidence (per 100,000 populations) among Non-Saudis by age group and sex.
- Age-standardized incidence rate and relative frequencies among Saudis by cancer site, sex.

Arabic Summary

Contains Arabic Summary of Cancer Statistics in Saudi Arabia for the Year 2012.

Table of Contents

Foreword	3
Introduction	4
Part I	7
Background on Saudi Arabia	8
Saudi Cancer Registry	8
Definitions of Statistical Terms	11
Part II	13
Reported Cancer Incidence Cases in Saudi Arabia, 2012	14
Adult Cancers in Saudi Arabia, 2012 (>14 years)	19
Childhood Cancers in Saudi Arabia, 2012 (≤ 14 years)	20
International Comparison of Age-Standardized Incidence Rates	23
Part III	25
Cancer Incidence for Most Common Sites, 2012	26
Female Breast Cancer (C50)	27
Colorectal (C18-C20)	29
Thyroid (C73)	31
Leukemia (C91-C95)	33
Non-Hodgkin Lymphoma (C82-C85; C96)	35
Liver (C22)	37
Lung (C33 - C34)	39
Hodgkin Disease (C 81)	41
Corpus Uteri (C 54)	43
Kidney (C64)	45
Sources	47
Part IV	48
Cancer among Non-Saudi Population 2012	49
Part V	52
Table 5.1.1 - Number of Cancer Cases Among Saudi Males by Primary Site and Age Groups, 2012	53
Table 5.1.2 - Number of Cancer Cases Among Saudi Females by Primary Site and Age Groups, 2012	54
Table 5.1.3 - Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site and Age Groups, 2012	55
Table 5.1.4 - Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site and Age Groups, 2012	56
Table 5.4.1 - Number of Cancer Cases Among Non-Saudi Males by Primary Site and Age Groups, 2012	57
Table 5.4.2 - Number of Cancer Cases Among Non-Saudi Females by Primary Site and Age Groups, 2012	58
Table 5.4.3 - Age-Specific Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Non-Saudi Males (per 100,000) by Primary Site and Age Groups, 2012	59
Table 5.4.4 - Age-Specific Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Non-Saudi Females (per 100,000) by Primary Site and Age Groups, 2012	60

Table 5.4.5 - Number Of New Cases by Primary Site and Years among Saudi Males, 1994 - 2012.....	61
Table 5.4.6 - Number Of New Cases by Primary Site and Years among Saudi Females, 1994 - 2012.....	62
Table 5.4.7 - Age Standardized Incidence Rate by Primary Site and Years among Saudi Males, 1994 - 2012.....	63
Table 5.4.8 - Age Standardized Incidence Rate by Primary Site and Years among Saudi Females, 1994 - 2012.....	64
Arabic Summary	65

PART I

MATERIALS AND METHODS

Background on Saudi Arabia

Saudi Arabia is a vast country extending over four-fifths of the Arabian Peninsula. It stretches from the Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* square kilometers in area and is divided into 13 administrative regions (Figure 1.1).



Figure 1.1 Administrative Regions of Saudi Arabia

The Saudi national population for year 2012 was 19,838,448**. Of these 9,962,397 (50.2%) were males and (49.8%) 9,876,051 were females. The Non-Saudi population in 2012 was 9,357,447**; of these 6,581,439 (70.3%) were males and 2,776,008(29.7%) females. Figures 1.2 and 1.3 show the Saudi and Non-Saudi population pyramids by sex and age group respectively.




Figure 1.2 Population Pyramids of Saudis (%) by Sex and Age Group, 2012




Figure 1.3 Population Pyramids of Non-Saudis (%) by Sex and Age Group, 2012

Saudi Cancer Registry

The Saudi Cancer Registry (SCR) is a population-based registry established in 1992 under Ministry of Health (MOH). In 2014 SCR was moved to Saudi Health Council under department of National Registries.

Objectives

The primary goal of the SCR is to define the population-based incidence of cancer in Saudi Arabia. Another objective is to support the early detection programs and cancer screening programs, as well as cancer research projects through providing accurate cancer data.

Organizational Structure

Representatives from MOH, King Faisal Specialist Hospital and Research Center, and Medical Services Departments of Ministry of Defense and Aviation, Ministry of Interior, Ministry of National Guard, King Saud University. Representatives are charged with the responsibility of overseeing the SCR's establishment, defining demographic and cancer related data to be collected, approving data requests, and reporting findings, as well as disseminating information collected while ensuring the confidentiality of all data reported to the SCR.

Additionally, five regional branches and five hospital-based offices were set up to ensure comprehensive data collection from all over the Kingdom (Figure 1.4).

* Source: Demographic and Health Indicators for Countries of the East Mediterranean, WHO, Regional Office for the EM, 1999

** Source: Central Department of Statistics & Information, Ministry of Economy and Planning

Regional Offices

1. Central Region: King Fahad Medical City in Riyadh, covering Riyadh, Qassim, and Hail Health Regions.
2. Eastern Region: King Fahad Hospital of the University, Al Khobar, covering Dammam, Al Ahsa, and Hafr Al-Batin Health Regions.
3. Western Region: East Jeddah General Hospital, Jeddah, covering Jeddah, Makkah, Taif and Qunfudah Health Regions.
4. Southern Region: Asir Central Hospital, Abha, covering Asir, Baha, Najran, Jazan and Bisha Health Regions.
5. Madinah/Northern Region: Maternity and Children Hospital, Madinah, covering Madinah, Tabuk, Jouf and Northern Health Regions.

Offices at the Medical Service Division or Oncology Department of the following establishments

6. King Faisal Specialist Hospital & Research Centre, Riyadh.
7. Ministry of Defense and Aviation, Armed Forces Hospitals, Riyadh.
8. Ministry of Interior, Security Forces Hospital, Riyadh.
9. Ministry of National Guard Hospitals, King Abdulaziz Medical City, Princess Norah Oncology Center, Jeddah.
10. King Khalid University Hospital, Riyadh.

Each of the SCR office operates under the supervision of directors who are responsible for the daily management. Staffing consists of tumor registrars and secretarial staff. The SCR Main Office indirectly supervises the regional offices to ensure accuracy and quality of data collected from all regions. Quality control processes include verification of site, morphology, and staging information as well as case linkage (tumor and patient), and consolidation of data. The Main Office also prepares annual reports for dissemination of information to the medical community, government establishments, international organizations and the media.

Format

The format of the current report is similar to the previous reports.




Figure 1.4 Organizational Chart of Saudi Cancer Registry

Data Management

A ministerial decree has categorized cancer as a mandatory notifiable disease. This ensures the opportunity for comprehensive data collection. The SCR strives for full access to cancer data from all Ministry of Health, governmental and private hospitals, as well as clinics and laboratories throughout the Kingdom. Cancer data are abstracted from patients' medical records, based on clinical and/or histopathological diagnosis, by SCR-trained cancer registrars.

The data abstract includes personal identification (name, ID Number, sex, age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICD-O-3), published by the World Health Organization (WHO), 2000. Effective from year 2001, changes were made in coding of cancer types and behaviors as well as staging according to International guidelines. The new SEER Summary Stage 2000 guidelines should result in increased accuracy and consistency in the coding of stage. There are some differences in the timing rules for determining stage and some sites are coded differently using the new guidelines. However, the new criteria and guidelines should improve the usefulness of staging as a predictor of prognosis and survival as the changes reflect a new understanding of the natural history of cancer. The new guidelines, SEER Summary Stage Manual 2000, are available on the web at: <http://seer.cancer.gov/tools/ssm/>

Cases diagnosed on or after 01 January 2008 are classified according to the updated ICD-O-3. Improvements in the understanding of cancer pathology over the last decade are reflected in the changes to ICD-O-3. While there have not been any changes in the primary site codes, there are significant changes regarding histology (cell types). Leukemias and lymphomas, particularly are affected. Some cases that were previously considered benign are now counted as malignant. Also small number of cancers that were previously coded as borderline tumors are now considered benign. Counts of ovarian cancers, lymphomas and or definition. However, as with the new staging guidelines, the ICD-O changes reflect advances in the understanding of the

pathology and behavior of cancers.

It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes. Since the WHO has not yet converted the ICD-10 hematopoietic disease behavior changes, our software, CanReg 4.33, cannot include these cases for analysis and they have been excluded. Every effort is made to accurately code patient and tumor information, to ensure that all data can be reviewed, linked, and consolidated, as appropriate, so that each malignancy is counted only once for statistical analysis. The computer software programs used for data entry and incidence tables output are CanReg 4.33, developed by the International Agency for Research on Cancer, (IARC) Lyon, France.

The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevant epidemiological and clinic pathological details for the 10 most common cancers among Saudi nationals for the year 2012. For each cancer site, the number and the percentage of all newly diagnosed cases for the year 2012, the age-standardized incidence rate (ASR) per 100,000 populations for each sex, and the specific cancer rank in comparison to all cancers for both sexes are presented. Useful international statistics for the specified cancer include the ranking of the cancer worldwide.

The relevant data incorporate details for all patients presented over the year 2012. For each cancer there are five figures:

1. An arithmetic line graph represents the age-specific incidence rate (AIR) for all age groups at five-year intervals. The graph is plotted by sex, where applicable.
2. A table lists the percentages of the most common histology sub-types for each specific cancer.
3. A pie chart shows the distribution of the clinical stages of each cancer such as localized, regional, distant metastasis and unknown.
4. A bar chart shows regional distribution of ASR for particular cancer across the administrative regions by males and females.
5. A bar chart shows comparison of age-standardized incidence rate (ASR) for each cancer type in Saudi Arabia with ASR in selected countries.

Notification

The data included in this report were abstracted up to July 2015. The incident cases which were identified after this date (late reporting) will be noted in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as case ascertainment processes are improved.

Moreover we don't have up to date statistics because we have to wait until all of the data from the regional cancer branches in Saudi Arabia has been collected before we can publish the annual incidence report. Also, the process of registering a cancer is complicated and there are a number of processes in place to ensure the data is of a high quality. This means there is usually a delay of around 3-2 years before the data is complete enough to be published.

Definitions of Statistical Terms

Age-Specific Incidence Rate (AIR)

The number of cancer cases occurring during a specific period in a population of a specific age and sex group, divided by the number of midyear population of that age and sex group.

Crude Incidence Rate (CIR)

The crude incidence rate for a cancer site is the total number of cases registered as a proportion of the total population. It denotes the approximate number of cases occurring in each 100,000 individuals. All rates are thus, expressed as per 100,000 population.

Cancer rates vary greatly with age and the crude rate is strongly influenced by the demographic structure of the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. It is not appropriate to compare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to assess time trends in registration data or compare incidence across geographical areas or between registries it is necessary to first standardize the rates with respect to age.

Age-Standardized Rate (ASR)

The Age-standardized rate is a summary measure of a rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Standardized Incidence Rate. The rate is expressed per 100,000 populations.

Age Class	Population
0 - 4	12,000
5 - 9	10,000
10 - 14	9,000
15 - 19	9,000
20 - 24	8,000
25 - 29	8,000
30 - 34	6,000
35 - 39	6,000
40 - 44	6,000
45 - 49	6,000
50 - 54	5,000
55 - 59	4,000
60 - 64	4,000
65 - 69	3,000
70 - 74	2,000
75 +	2,000
Total	100,000

**** Doll R. Payne P. Waterhouse J. Cancer Incidence in Five Continents Vol. I. International Union against Cancer. 1966**

Cumulative Incidence rate

Cumulative incidence rate is the probability or risk of individuals developing the disease during a specified period. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop a particular cancer before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age standardized rate, it permits comparison between populations of different age structures. In this report the age ranges 0-64 and 0-74 years are used. The cumulative rate is the summation of the cancer age-specific rates; which are computed for five-year age intervals. The cumulative rate is five times the sum of the agespecific rates calculated over the five-year age groups.

ICD - 10

The World Health Organization's International Classification of Diseases, tenth edition.

ICD - O - 3

The World Health Organization's International Classification of Diseases for Oncology, 3rd Edition has been the standard coding system for neoplasms for over 25 years. The coding system includes a four character code for primary site, a four-digit numeric code for cell type, one-digit code for behavior and a one-digit code for tumor aggressiveness (grade).

Incidence rate

An incidence rate is defined as the rate at which a new event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined time period, divided by the population at risk of developing that disease.

Mean

The simple mathematical average of two or more numbers.

Median

The midpoint of the range numbers that are arranged in order of value.

Metastasis

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and or visceral organs.

Range

It is the difference between the maximum and minimum values in a set of observations.

Rank

This measure reflects the importance of a specific cancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency.

Ratio

It is the relation between two quantities. The first quantity as numerator and the second as denominator.

Relative Frequency

This statistic is defined as the number of specific cancer cases registered relative to the total number of all cancer. It is expressed as a percentage.

Summary Stage

Staging is the grouping of cancer cases into broad categories based on the extent of disease.

PART II

OVERVIEW OF CANCER INCIDENCE

2012

Reported Cancer Incidence Cases in Saudi Arabia, 2012

Between January 01 and December 31, 2012, the total number of cancer incident cases reported to the Saudi Cancer Registry (SCR) was 14,846. Overall cancer was more among women than men; it affected 7,048 (47.5%) males and 7,798 (52.5%) females. Total of 11,333 cases were reported among Saudis, and 3,393 among Non-Saudis and 120 of Unknown Nationality.

The total number of cases excluded from analysis include 120 cases of Unknown Nationalities, other exclusions were 316 *in situ* cases ; the current software program CanReg-4 version 4.33, does not include *in situ* cases in the statistical analysis. Also, 74 were ICD-O-3 coded cases that failed to convert to ICD-10 codes as described in the Data Management. This puts the total number of exclusions from the analysis as 510 cases. Table 2.1 illustrates the distribution of the cases by sex, and nationality.

Diagnosis of malignancy was confirmed Histologically in 88.3% of the cases, and Hematological & Cytologically in 5.5% of cases , Clinically confirmed cases were 0.2%, Tumor Marker 0.1%, Radiologically confirmed cases were 2.6%, cases confirmed by Death Certificate were 2.5% and the method of diagnosis was unknown for 0.7% of the cases.

Total of 14,336 cases were analyzed, of which 11,034 (76.9%) were Saudis and 3,302 (23%) were Non-Saudis. Among Saudis 5,067 (45.9%) were male and 5,967 (54.1%) were female. The male to female ratio was 117:100. The crude incidence rate (CIR) of all cancers among Saudis population was 55.6/100,000 (50.8/100,000 among males and 60.3/100,000 among females). The overall age-standardized incidence rate (ASR) for Saudis was 78.1/100,000 in males and 86.7/100,000 in females.

For all sites, the age-specific incidence rate (AIR) increased with age for both Saudi males and females. The median age at diagnosis for men was 58 years; range (0 -122) and 51 years for women; range (0-112).

Saudis						Unknown Nationality*			Non-Saudis						
Analyzed				Non-analyzed*					Analyzed				Non-analyzed*		
Male	Female	Total		Male	Female	Total			Male	Female	Total		Male	Female	Total
5067	5967	11034		154	145	299			52	68	120		1724	1578	3302

Table 2.1 Distribution of cancer cases in Saudi Arabia by Nationality and Sex 2012

Cancer among Saudi 2012

As explained earlier the total numbers of cancer cases analyzed among Saudi during the year 2012 was 11,035. Following are figures presenting the percentage distributions of (cancer incidence) and most frequent types of cancers among Saudis by sex and age-group.




Figure 2.1 Percentage Distribution of Cancer Incidence among Saudis by Sex according to Age Group, 2012




Figure 2.2 Percentage Distribution of Most Frequent Types of Cancer by Sex and age-groups among Saudis, 2012

Cancer	No.	%
Breast	1567	14.2
Colorectal	1230	11.1
Thyroid	890	8.1
Leukemia	746	6.8
NHL	740	6.7
Liver	474	4.3
Lung	463	4.2
Hodgkin Disease	355	3.2
Corpus Uteri	315	2.9
Kidney	313	2.8

Table: 2.3 Ten Most Common Cancers among Saudis, 2012 for All Ages.

Male			Female		
5067			5967		
Colorectal	675	13.3%	Breast	1542	25.8%
NHL	424	8.4%	Thyroid	697	11.7%
Leukemia	418	8.2%	Colorectal	555	9.3%
Liver	344	6.8%	Leukemia	328	5.5%
Lung	336	6.6%	NHL	316	5.3%
Prostate	288	5.7%	Corpus Uteri	315	5.3%
Hodgkin Disease	194	3.8%	Ovary	193	3.2%
Bladder	193	3.8%	Hodgkin Disease	161	2.7%
Thyroid	193	3.8%	Cervix Uteri	137	2.3%
Kidney	190	3.7%	Liver	130	2.2%

Figure 2.3 Ten Most Common Cancers among Saudis by sex, 2012




Figure 2.4 Age-Specific Incidence Rate (AIR) for All Cancers among Saudis, 2012

ICD-10	Site	Male						Female					
		No.	%	Crude	ASR	Cumulative Rate		No.	%	Crude	ASR	Cumulative Rate	
				Rate	World	0-64	0-74			Rate	World	0-64	0-74
All	All sites Total	5067	100.0	50.8	78.1	39.4	86.7	5967	100.0	60.3	86.7	55.4	95.4
Not C44	All sites but C44	4898	97.0	49.1	75.3	38.6	83.9	5835	97.8	59	84.6	54.5	93.2
C00	Lip	4	0.1	0	0.1	0.0	0.1	4	0.1	0	0.1	0.0	0.1
C01-C02	Tongue	42	0.8	0.4	0.6	0.4	0.7	51	0.9	0.5	0.8	0.4	1.0
C03-C06	Mouth	37	0.7	0.4	0.6	0.3	0.7	33	0.6	0.3	0.5	0.3	0.6
C07-C08	Salivary glands	8	0.2	0.1	0.1	0.1	0.2	28	0.5	0.3	0.4	0.2	0.4
C09	Tonsil	2	0	0	0	0.0	0.0	2	0	0	0	0.0	0.1
C10	Other Oropharynx	4	0.1	0	0.1	0.0	0.1	3	0.1	0	0	0.0	0.0
C11	Nasopharynx	111	2.2	1.1	1.6	1.3	1.7	45	0.8	0.5	0.6	0.5	0.5
C12-C13	Hypopharynx	6	0.1	0.1	0.1	0.0	0.2	17	0.3	0.2	0.3	0.2	0.3
C14	Pharynx unspec.	1	0	0	0	0.0	0.0	2	0	0	0	0.0	0.0
C15	Oesophagus	83	1.6	0.8	1.4	0.5	1.6	63	1.1	0.6	1	0.3	1.0
C16	Stomach	186	3.7	1.9	3.2	1.4	3.8	94	1.6	0.9	1.5	0.7	1.9
C17	Small intestine	34	0.7	0.3	0.6	0.3	0.7	25	0.4	0.3	0.4	0.3	0.5
C18	Colon	391	7.7	3.9	6.5	3.5	7.8	324	5.4	3.3	5.3	3.4	6.5
C19-C20	Rectum	284	5.6	2.8	4.6	3.0	5.8	231	3.9	2.3	3.7	2.1	3.9
C21	Anus	23	0.5	0.2	0.4	0.2	0.5	9	0.2	0.1	0.2	0.0	0.2
C22	Liver	344	6.8	3.4	6.3	2.5	7.7	130	2.2	1.3	2.3	1.0	2.9
C23-C24	Gallbladder etc.	68	1.3	0.7	1.2	0.6	1.6	90	1.5	0.9	1.6	0.7	1.9
C25	Pancreas	155	3.1	1.6	2.6	1.5	3.0	87	1.5	0.9	1.5	0.8	1.6
C30-C31	Nose, sinuses etc.	17	0.3	0.2	0.3	0.1	0.4	13	0.2	0.1	0.2	0.2	0.2
C32	Larynx	59	1.2	0.6	1.1	0.5	1.3	12	0.2	0.1	0.2	0.1	0.2
C33-C34	Trachea,Bronchus,Lung	336	6.6	3.4	5.9	2.6	7.1	127	2.1	1.3	2.2	1.1	2.4
C37-C38	Other Thoracic organs	18	0.4	0.2	0.2	0.2	0.2	10	0.2	0.1	0.1	0.0	0.1
C40-C41	Bone	85	1.7	0.9	0.9	0.6	0.7	60	1	0.6	0.7	0.4	0.6
C43	Melanoma of Skin	8	0.2	0.1	0.1	0.0	0.1	16	0.3	0.2	0.3	0.1	0.3
C44	Other Skin	169	3.3	1.7	2.7	1.0	2.9	132	2.2	1.3	2.1	1.0	2.3
C45	Mesothelioma	12	0.2	0.1	0.2	0.0	0.2	2	0	0	0	0.0	0.0
C46	Kaposi sarcoma	24	0.5	0.2	0.4	0.2	0.4	2	0	0	0	0.0	0.0
C47;C49	Connective,Soft tissue	86	1.7	0.9	1	0.5	0.9	59	1	0.6	0.7	0.4	0.6
C50	Breast	25	0.5	0.3	0.4	0.2	0.5	1542	25.8	15.6	22.1	16.9	24.5
C51	Vulva	-	-	-	-	-	-	8	0.1	0.1	0.1	0.1	0.1
C52	Vagina	-	-	-	-	-	-	4	0.1	0	0.1	0.0	0.1
C53	Cervix Uteri	-	-	-	-	-	-	137	2.3	1.4	2.1	1.5	2.3
C54	Corpus Uteri	-	-	-	-	-	-	315	5.3	3.2	5.4	3.0	7.2
C55	Uterus unspec.	-	-	-	-	-	-	48	0.8	0.5	0.8	0.4	1.2
C56	Ovary	-	-	-	-	-	-	193	3.2	2	3	1.6	3.5
C57	Other Female Genital	-	-	-	-	-	-	15	0.3	0.2	0.2	0.1	0.4
C58	Placenta	-	-	-	-	-	-	3	0.1	0	0	0.0	0.0
C60	Penis	3	0.1	0	0.1	0.0	0.1	-	-	-	-	-	-
C61	Prostate	288	5.7	2.9	5.3	1.6	5.8	-	-	-	-	-	-
C62	Testis	82	1.6	0.8	0.8	0.6	0.6	-	-	-	-	-	-
C63	Other male genital	0	0	0	0	0.0	0.0	-	-	-	-	-	-
C64	Kidney	190	3.7	1.9	2.8	1.4	3.2	123	2.1	1.2	1.8	1.3	2.0
C65	Renal Pelvis	8	0.2	0.1	0.1	0.1	0.2	0	0	0	0	0.0	0.0
C66	Ureter	2	0	0	0	0.0	0.1	0	0	0	0	0.0	0.0
C67	Bladder	193	3.8	1.9	3.2	1.6	3.4	52	0.9	0.5	0.9	0.5	1.0
C68	Other Urinary organs	1	0	0	0	0.0	0.0	1	0	0	0	0.0	0.0
C69	Eye	23	0.5	0.2	0.3	0.1	0.1	19	0.3	0.2	0.2	0.1	0.1
C70-C72	Brain, Nervous system	175	3.5	1.8	2.2	1.5	2.2	123	2.1	1.2	1.5	1.0	1.3
C73	Thyroid	193	3.8	1.9	2.7	1.9	3.0	697	11.7	7	8.3	6.4	8.0
C74	Adrenal gland	18	0.4	0.2	0.2	0.1	0.2	17	0.3	0.2	0.2	0.1	0.1
C75	Other Endocrine	9	0.2	0.1	0.1	0.1	0.1	1	0	0	0	0.0	0.0
C81	Hodgkin disease	194	3.8	1.9	2	1.4	1.7	161	2.7	1.6	1.6	1.1	1.4
C82-C85;C96	Non-Hodgkin lymphoma	424	8.4	4.2	6.2	3.2	7.0	316	5.3	3.2	4.7	2.7	5.5
C88	Immunoproliferative dis.	0	0	0	0	0.0	0.0	1	0	0	0	0.0	0.0
C90	Multiple Myeloma	71	1.4	0.7	1.2	0.6	1.6	52	0.9	0.5	0.9	0.4	1.2
C91	Lymphoid Leukaemia	229	4.5	2.3	2.6	1.3	2.0	132	2.2	1.3	1.4	0.8	1.1
C92-C94	Myeloid Leukaemia	168	3.3	1.7	2.1	1.1	1.9	171	2.9	1.7	2.1	1.4	1.9
C95	Leukaemiaunspec.	21	0.4	0.2	0.3	0.2	0.3	25	0.4	0.3	0.3	0.1	0.3
Other	Other & unspecified	153	3	1.5	2.5	1.3	2.7	140	2.3	1.4	2.3	1.3	2.5

Table 2.4 Number, Percentage, ASR, CIR and Cumulative Rates (per 100,000) of New Cases by Primary Site and Sex among Saudis, 2012

Adult Cancer in Saudi Arabia, 2012 (>14 years)

Between January and December 2012, the total number of adult cancer incidence cases reported were 13,991. Overall cancer was more in females than in males. Cancer affected 6,586 (47.1%) males and 7,405 (52.9%) female with male to female a ratio of 88:100. Of all cases, there were 10,623 Saudis, 3,253 of Non-Saudis and 115 of unknown nationalities. As shown on table 2.5.1, the total number of analyzed cases were 13,492.

Saudis						Unknown Nationality*			Non-Saudis					
Analyzed			Non-analyzed*						Analyzed			Non-analyzed*		
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
4677	5652	10329	153	141	294	48	67	115	1658	1505	3163	50	40	90

Table 2.5.1 Distribution of Reported Adult Cancer Cases in Saudi Arabia by Nationality and Sex, 2011

Cancer	No.	%
Breast	1567	15.2
Colorectal	1230	11.9
Thyroid	879	8.5
NHL	688	6.7
Liver	461	4.5
Lung	460	4.5
Leukemia	456	4.4
Corpus Uteri	315	3.0
Hodgkin Disease	310	3.0
Skin	298	2.9

Table 2.5.2 Ten Common Cancer among Saudi Adults, 2012

Male			Female		
4677			5652		
Colorectal	675	14.4%	Breast	1542	27.3%
NHL	395	8.4%	Thyroid	687	12.2%
Liver	338	7.2%	Colorectal	555	9.8%
Lung	333	7.1%	Corpus Uteri	315	5.6%
Prostate	288	6.2%	NHL	293	5.2%
Leukemia	244	5.2%	Leukemia	212	3.8%
Bladder	192	4.1%	Ovary	190	3.4%
Thyroid	192	4.1%	Hodgkin disease	140	2.5%
Stomach	186	4.0%	Cervix Uteri	137	2.4%
Hodgkin Disease	170	3.6%	Skin	130	2.3%

Figure 2.6 Ten Most Common Cancer among Saudi Adults by Sex, 2012

* Unknown nationalities, in situ cases and ICD-10 conversion failures are excluded from analysis

Childhood Cancer in Saudi Arabia, 2012 (≤ 14 years)

The total incident cases reported among children (0-14 years) between January and December 2012 were 851. This represents 5.7% of the total number of cancers in Saudi Arabia. The reported incidents show that cancer was more common among boys than girls, 459 (53.9%) cases were reported among boys and 392 (46.1%) among girls. The reported cancer cases were 708 Saudis, 138 non-Saudi and 5 of "unknown nationality". Based on Table 2.6.1, the total number of analyzed cases were 840 including 703(83.7%) Saudi and 137 (16.3%) Non-Saudi. Among Saudi, 389 (55.3%) were males and 314 (44.7%) were female. The male to female ratio among Saudis was 123:100.

Childhood cancers accounted for 6.2% of all cancer among Saudis. Table 2.6.2. shows that the leading cancer among Saudi children was Leukemia, which accounted for 41.3 %, followed by Brain, CNS 12.1% then NHL 7.4 % then Hodgkin Disease 6.4% and Bone 6.3% . Figure 2.7 shows the top ten sites by sex and frequency, and Table 2.6.3 shows the number and proportion of the morphological types for the most common types of cancer.

Saudis						Unknown Nationality*			Non-Saudis					
Analyzed			Non-analyzed*						Analyzed			Non-analyzed*		
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
389	314	703	1	4	5	4	1	5	64	73	137	1	0	1

Table 2.6.1 Distribution of Reported Childhood Cancer in Saudi Arabia by Nationality and Sex, 2012

Cancer	No.	%
Leukemia	290	41.3
Brain, CNS	85	12.1
NHL	52	7.4
Hodgkin disease	45	6.4
Bone	44	6.3
Connective, Soft tissue	33	4.7
Eye	33	4.7
Kidney	32	4.6
Adrenal gland	22	3.1
Liver	13	1.8

Table 2.6.2 Ten Most Common Cancer among Saudi Children, 2012


Boys				Girls		
	389				314	
Leukemia	174	44.7%		Leukemia	116	36.9%
Brain, CNS	46	11.8%		Brain, CNS	39	12.4%
NHL	29	7.5%		NHL	23	7.3%
Hodgkin disease	24	6.2%		Bone	23	7.3%
Kidney	21	5.4%		Hodgkin disease	21	6.7%
Bone	21	5.4%		Connective, Soft tissue	19	6.1%
Eye	17	4.4%		Eye	16	5.1%
Connective, Soft tissue	14	3.6%		Adrenal gland	12	3.8%
Adrenal gland	10	2.6%		Kidney	11	3.5%
Liver	6	1.5%		Thyroid	10	3.2%

Figure 2.7 Ten Most Common Cancer among Saudi Children by Sex, 2012

Primary Site	Code	Morphology	Male	%	Female	%
Leukemia	9863	Precursor B-cell lymphoblastic leukemia	73	42.0	45	38.8
	9835	Precursor cell lymphoblastic leukemia, NOS	32	18.4	24	20.7
	9837	Precursor T-cell lymphoblastic leukemia	22	12.6	7	6.0
	9861	Acute myeloid leukemia, NOS	10	5.7	8	6.9
	9866	Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	6	3.4	3	2.6
	9891	Acute monocytic leukemia	5	2.9	2	1.7
	9896	Acute myeloid leukemia, t(8;21)(q22;q22)	4	2.3	3	2.6
	9826	Burkitt cell leukemia	4	2.3	1	.9
	9801	Acute leukemia, NOS	3	1.7	6	5.2
	9946	Juvenile myelomonocytic leukemia	3	1.7	4	3.4
		Others	12	6.9	13	11.2
		Total	174	100	116	100
Brain,CNS	9470	Medulloblastoma, NOS	16	34.8	13	33.3
	9380	Glioma, malignant	6	13.0	10	25.6
	9392	Ependymoma, anaplastic	5	10.9	2	5.1
	9391	Ependymoma, NOS	4	8.7	1	2.6
	9400	Astrocytoma, NOS	3	6.5	3	7.7
	9508	Atypical teratoid/rhabdoid tumor	3	6.5	1	2.6
	9440	Glioblastoma, NOS	2	4.3	2	5.1
	9400	Astroblastoma	1	2.2	1	2.6
	9471	Desmoplastic nodular medulloblastoma	1	2.2	1	2.6
		Others	5	10.9	5	12.8
		Total	46	100	39	100
NHL	9687	Burkitt lymphoma, NOS	11	37.9	8	34.8
	9754	Langerhans cell histiocytosis, disseminated	4	13.8	0	0
	9590	Malignant lymphoma, NOS	3	10.3	1	4.3
	9680	Malignant lymphoma, large B-cell, diffuse, NOS	2	6.9	5	21.7
	9700	Mycosis fungoides	2	6.9	2	8.7
	9729	Precursor T-cell lymphoblastic lymphoma	2	6.9	4	17.4
		Others	5	17.2	3	13.0
		Total	29	100	23	100
Hodgkin Disease	9663	Hodgkin lymphoma, nodular sclerosis, NOS	12	50.0	12	57.1
	9652	Hodgkin lymphoma, mixed cellularity, NOS	5	20.8	4	19.0
	9650	Hodgkin lymphoma, NOS	3	12.5	2	9.5
	9659	Hodgkin lymphoma, nodular lymphocyte predominance	2	8.3	1	4.8
	9651	Hodgkin lymphoma, lymphocyte-rich	1	4.2	0	0.0
		Others	1	4.2	2	9.5
		Total	24	100	21	100
Bone	9260	Ewing sarcoma	7	33.3	10	43.5
	9180	Osteosarcoma, NOS	4	19.0	7	30.4
	9364	Peripheral neuroectodermal tumor	3	14.3	1	4.3
	9261	Adamantinoma of long bones	2	9.5	0	0.0
	8920	Alveolar rhabdomyosarcoma	1	4.8	0	0
	9473	Primitive neuroectodermal tumor, NOS	1	4.8	0	0.0
	9181	Chondroblastic osteosarcoma	0	0.0	3	13.0
	8000	Neoplasm, malignant	0	0.0	1	4.3
		Others	3	14.3	1	4.3
		Total	21	100	23	100
Connective Tissue	8910	Embryonal rhabdomyosarcoma, NOS	4	28.6	2	10.5
	9500	Neuroblastoma, NOS	2	14.3	8	42.1
	9364	Peripheral neuroectodermal tumor	2	14.3	5	26.3
	8805	Undifferentiated sarcoma	2	14.3	0	0.0
	8806	Desmoplastic small round cell tumor	1	7.1	0	0.0
	8900	Rhabdomyosarcoma, NOS	0	0.0	3	15.8
		Others	3	21.4	1	5.3
		Total	14	100	19	100

Table 2.6.3 Number and Percentage of Morphological Types for the Most Common types of Cancer among Saudi Children, 2012

Table 2.6.3 Continued

Primary Site	Code	Morphology	Male	%	Female	%
Eye	9510	Retinoblastoma, NOS	10	58.8	15	93.8
	9512	Retinoblastoma, undifferentiated	2	11.8	0	0.0
	8910	Embryonal rhabdomyosarcoma, NOS	1	5.9	1	6.3
	9240	Mesenchymal chondrosarcoma	1	5.9	0	0.0
	9500	Neuroblastoma, NOS	1	5.9	0	0.0
	9511	Retinoblastoma, differentiated	1	5.9	0	0.0
	8900	Rhabdomyosarcoma, NOS	1	5.9	0	0.0
		Total	17	100	16	100
Kidney	8960	Nephroblastoma, NOS	18	85.7	7	63.6
	8964	Clear cell sarcoma of kidney	1	4.8	1	9.1
	8260	Papillary adenocarcinoma, NOS	1	4.8	0	0.0
	8312	Renal cell carcinoma, NOS	1	4.8	0	0.0
	8963	Malignant rhabdoid tumor	0	0.0	2	18.2
	9500	Neuroblastoma, NOS	0	0.0	1	9.1
		Total	21	100	11	100
Adrenal Gland	9500	Neuroblastoma, NOS	10	100	8	66.7
	8370	Adrenal cortical carcinoma	0	0	1	8.3
	9490	Ganglioneuroblastoma	0	0	2	16.7
	9080	Teratoma, malignant, NOS	0	0	1	8.3
		Total	10	100	12	100
Liver	8970	Hepatoblastoma	2	33.3	7	100
	8170	Hepatocellular carcinoma, NOS	4	66.7	0	0.0
		Total	6	100	7	100

International Comparison of Age-Standardized Incidence Rates

Worldwide, GLOBOCAN, 2012 estimated that 14,090,149 people developed cancer in 2012. Of These, 80,142,73 (56.9%) were in developing countries and 60,758,76 (43.1%) in developed countries. In men, ASR is high in Northern America, Europe, and Australia\New Zealand while the lowest ASR is in Western/ Middle Africa and South-Central Asia. As in males, the regions with the highest ASR in females are Northern America, Europe, and Australia\New Zealand while the lowest ASR in Middle/Northern/Western Africa and in South-Eastern Asia and South-Central Asia. According to 2012 estimates, the most common cancer site worldwide among men was lung cancer, followed by prostate, colorectal, stomach then liver. However in developed countries prostate was the leading cancer followed by lung, colorectal, then bladder followed by stomach, while in developing countries lung cancer was first followed by liver, stomach, prostate and NHL cancers. In women, the most common cancer site was breast followed by colorectal, lung, cervix uteri cancers and corpus uteri. In developing countries among women, breast cancer was the most common followed by cervix uteri, lung, then colorectal, and stomach. While in the developed countries breast cancer was the leading cancer followed by cancers of the colorectal, corpus uteri then Hodgkin disease.




Figure 2.9.1 Comparison of ASR* for Saudi Males with Selected Countries**




Figure 2.9.2 Comparison of ASR* for Saudi Female with Selected Countries**

*ASR per 100,000

**Source for this information is summarized on page 51

PART III
CANCER INCIDENCE
FOR MOST COMMON SITES 2012

Cancer Incidence for Most Common Sites, 2012

In this section, the incidence of the most common cancers among Saudi males and females are outlined in accordance to their relative frequencies. The relevant data incorporate details for all patients presented over the period of January through December 2012.

Site	Male	Female	All	%
Breast	25	1542	1567	14.2
Colorectal	675	555	1230	11.1
Thyroid	193	697	890	8.1
Leukemia	418	328	746	6.8
NHL	424	316	740	6.7
Liver	344	130	474	4.3
Lung	336	127	463	4.2
Hodgkin disease	194	161	355	3.2
Corpus Uteri	-	315	315	2.9
Kidney	190	123	313	2.8

Table 3.1 Most Common Cancer among Saudis by Sex, 2012

Female Breast Cancer (C50)

There were 1,542 female breast cancer cases for year 2012. Breast cancer ranked the 1st among females accounting for 25.8% of all newly diagnosed female cancers (5,967) in year 2012. The ASR was 22.1/100,000 for female population. The median age at diagnosis was 49 years (Range 20-106 years).




Figure 3.1.1 Age-Specific Incidence Rate (AIR) for Female Breast Cancer in Saudi Arabia, 2012

ICD O-3	Morphology	Female	%
8500	Infiltrating duct carcinoma, NOS	1214	78.4
8520	Lobular carcinoma, NOS	75	4.9
8522	Infiltrating duct and lobular carcinoma	53	3.4
8000	Neoplasm, malignant	41	2.7
8010	Carcinoma, NOS	34	2.2
8523	Infiltrating duct mixed with other types of carcinoma	23	1.5
9020	Phyllodes tumor, malignant	19	1.2
8050	Papillary carcinoma, NOS	16	1.0
8480	Mucinous adenocarcinoma	11	0.7
8510	Medullary carcinoma, NOS	9	0.6
	Others	47	3.0

Table 3.1.1 Morphological Distribution of Female Breast Cancer in Saudi Arabia, 2012




Figure 3.1.2 Stage Distribution of Female Breast Cancer in Saudi Arabia, 2012




Figure 3.1.4 Comparison of ASR* for Female Breast Cancer among Saudi Females with ASR in Selected Countries**

*ASR per 100,000

** Source for this information is summarized on page 51

Colorectal (C18-C20)

There were 1,230 cases of colorectal cancer accounting for 11.1% of all newly diagnosed cases in year 2012. This cancer ranked the 1st among male and the 3rd among female. It affected 675 (54.9%) males and 555 (45.1 %) females with a male to female ratio of 122:100. The ASR males was 11.1/100,000 and for females 9.0/100,000. The median age at diagnosis was 59 years among males (range 19-112 years) and 58 years among females (range 17-111 years).

Figure 3.2.1 Age-Specific Incidence Rate (AIR) for Colorectal Cancer in Saudi Arabia, 2012




Figure 3.2.1 Age-Specific Incidence Rate (AIR) for Colorectal Cancer in Saudi Arabia, 2012

ICD O-3	Morphology	Male	%	Female	%
8140	Adenocarcinoma, NOS	518	76.7	439	79.1
8480	Mucinous adenocarcinoma	58	8.6	36	6.5
8000	Neoplasm, malignant	17	2.5	14	2.5
8210	Adenocarcinoma in adenomatous polyp	14	2.1	7	1.3
8260	Adenocarcinoma in tubulovillous adenoma	13	1.9	19	3.4
8490	Signet ring cell carcinoma	12	1.8	6	1.1
8010	Carcinoma, NOS	10	1.5	7	1.3
8481	Mucin-producing adenocarcinoma	9	1.3	5	0.9
8261	Adenocarcinoma in villous adenoma	6	0.9	9	1.6
8246	Neuroendocrine carcinoma, NOS	5	0.7	5	0.9
	Others	13	1.9	8	1.4

Table 3.2.1 Morphological Distribution of Colorectal Cancer in Saudi Arabia, 2012




Figure 3.2.2 Stage Distribution of Colorectal Cancer in Saudi Arabia, 2012




Figure 3.2.4 Comparison of ASR* for Colorectal Cancer among Saudi with ASR in Selected countries**

*ASR per 100,000

** Source for this information is summarized on page 51

Thyroid (C73)

There were 890 cases of thyroid cancer accounting for 8.1 %of all newly diagnosed cases for the year 2012. This cancer ranked 2ed among female and 8th among male population. It affected 697 (78.3%) females and 193 (21.7%) males, with a female to male ratio of 361:100. The ASR was 8.3 /100,000 for females and 2.7/100,000 for male. The median age at diagnosis was 39 years among females (range 7-96 years) and 48 years among males (range 14-85 years).




Figure 3.3.1 Age-Specific Incidence Rate (AIR) for Thyroid Cancer in Saudi Arabia, 2012

ICD O-3	Morphology	Male	%	Female	%
8260	Papillary adenocarcinoma, NOS	101	52.3	359	51.5
8340	Papillary carcinoma, follicular variant	18	9.3	135	19.4
8341	Papillary microcarcinoma	18	9.3	67	9.6
8330	Follicular adenocarcinoma, NOS	7	3.6	26	3.7
8343	Papillary carcinoma, encapsulated	9	4.7	23	3.3
8335	Follicular carcinoma, minimally invasive	4	2.1	19	2.7
8344	Papillary carcinoma, columnar cell	11	5.7	18	2.6
8290	Oxyphilic adenocarcinoma	3	1.6	13	1.9
8050	Papillary carcinoma, NOS	3	1.6	11	1.6
8510	Medullary carcinoma, NOS	5	2.6	6	0.9
	Others	14	7.3	20	2.8

Table 3.3.1 Morphological Distribution of Thyroid Cancer in Saudi Arabia, 2012




Figure 3.3.2 Stage Distribution of Thyroid Cancer in Saudi Arabia, 2012




Figure 3.3.4 Comparison of ASR* for Thyroid Cancer among Saudi with ASR in Selected countries**

*ASR per 100,000

** Source for this information is summarized on page 51

Leukemia (C91-C95)

There were 746 cases of leukemia accounting for 6.8 % of all newly diagnosed cancers in year 2012. This cancer ranked 3rd for males and the 4th for females. It affected 418 (56.0%) males and 328 (44.0%) females with a male to female ratio of 127:100. The ASR in males was 5.0/100,000 and 3.8/100,000 for females. The median age at diagnosis is 21 years among males (range 0-92 years) and 27 years among females (range 0-94 years).




Figure 3.4.1 Age-Specific Incidence Rate (AIR) for Leukemia in Saudi Arabia, 2012

ICD O-3	Morphology	Male	%	Female	%
9836	Precursor B-cell lymphoblastic leukemia	93	22.2	66	20.1
9861	Acute myeloid leukemia, NOS	50	12.0	52	15.9
9823	B-cell chronic lymphocytic leukemia/small lymphocytic lymphom	44	10.5	23	7.0
9835	Precursor cell lymphoblastic leukemia, NOS	44	10.5	31	9.5
9863	Chronic myeloid leukemia, NOS	33	7.9	39	11.9
9837	Precursor T-cell lymphoblastic leukemia	32	7.7	9	2.7
9866	Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	15	3.6	17	5.2
9875	Chronic myelogenous leukemia, BCR/ABL positive	13	3.1	13	4.0
9800	Leukemia, NOS	12	2.9	9	2.7
9891	Acute monocytic leukemia	11	2.6	7	2.1
	Others	71	17.0	62	19.0

Table 3.4.1 Morphological Distribution of Leukemia in Saudi Arabia, 2012




Figure 3.4.3 ASR* Regional Distribution of Leukemia in Saudi Arabia with ASR in Selected Countries

*ASR per 100,000

** Source for this information is summarized on page 51

Non-Hodgkin Lymphoma (C82-C85; C96)

There were 740 cases of Non-Hodgkin Lymphoma accounting for 6.7 % of all newly diagnosed cancers in year 2012. This cancer ranked 2nd male population and 6th among female population. It affected 424 (57.3%) males and 316 (42.7%) females with a male to female ratio of 134:100. The ASR for males was 6.2/100,000 and 4.7/100,000 for females. The median age at diagnosis was 53 years among males (range 1-109 years) and 54 years among females (range 2-100 years).




Figure 3.5.1 Age-Specific Incidence Rate (AIR) for NHL in Saudi Arabia, 2012

ICD O-3	Morphology	Male	%	Female	%
9680	Malignant lymphoma, large B-cell, diffuse, NOS	218	51.4	157	49.7
9687	Burkitt lymphoma, NOS	27	6.4	14	4.4
9591	Malignant lymphoma, non-Hodgkin, NOS	27	6.4	10	3.2
9590	Malignant lymphoma, NOS	26	6.1	14	4.4
9699	Marginal zone B-cell lymphoma, NOS	16	3.8	19	6.0
9700	Mycosis fungoides	14	3.3	18	5.7
9702	Mature T-cell lymphoma, NOS	12	2.8	7	2.2
9714	Anaplastic large cell lymphoma, T cell and Null cell type	11	2.6	6	1.9
9698	Follicular lymphoma, grade 2	9	2.1	15	4.7
9670	Malignant lymphoma, small B lymphocytic, NOS	8	1.9	3	0.9
	Others	56	13.2	53	83.2

Table 3.5.1 Morphological Distribution of NHL in Saudi Arabia, 2012




Figure 3.5.2 Stage Distribution of NHL in Saudi Arabia, 2012




Figure 3.5.4 Comparison of ASR* for NHL among Saudi with ASR in Selected Countries**

*ASR per 100,000

** Source for this information is summarized on page 51

Liver (C22)

There were 474 cases of liver cancer accounting for 4.3 % of all newly diagnosed cases in year 2012. This cancer ranked 4th in males and 10th in females. It affected 344 (72.6 %) males and 130 (27.4%) females with a male to female ratio of 264:100. The ASR was 6.3/100,000 for males and 2.3/100,000 for females. The median age at diagnosis was 68 years in males (range 1-106 years) and 66 years in females (range 0-100 years).




Figure 3.6.1 Age-Specific Incidence Rate (AIR) for Liver Cancer in Saudi Arabia, 2012

ICD O-3	Morphology	Male	%	Female	%
8170	Hepatocellular carcinoma, NOS	300	87.2	86	66.2
8160	Cholangiocarcinoma	15	4.4	12	9.2
8000	Neoplasm, malignant	12	3.5	10	7.7
8140	Adenocarcinoma, NOS	5	1.5	8	6.2
8180	Combined hepatocellular carcinoma and cholangiocarcinoma	4	1.2	2	1.5
8010	Carcinoma, NOS	2	0.6	0	0.0
8970	Hepatoblastoma	2	0.6	8	6.2
8174	Hepatocellular carcinoma, clear cell type	1	0.3	0	0.0
8171	Hepatocellular carcinoma, fibrolamellar	1	0.3	0	0.0
8830	Malignant fibrous histiocyoma	1	0.3	0	0.0
	Others	1	0.3	4	3.1

Table 3.6.1 Morphological Distribution of Liver Cancer in Saudi Arabia, 2012




Figure 3.6.2 Stage Distribution of Liver Cancer in Saudi Arabia, 2012




Figure 3.6.4 Comparison of ASR* for Liver Cancer among Saudis with ASR in Selected Countries**

* ASR per 100,000

** Source for this information is summarized on page 51

Lung (C33 - C34)

There were 463 cases of lung cancer accounting for 4.2% of all diagnosed cases in year 2012. Lung cancer ranked 5th among male and 12th among female. It affected 336 (72.6%) males and 127 (27.4 %) females with a male to female ratio of 264:100. The ASR was 5.9/100,000 for males and 2.2 /100,000 for females. The median age at diagnosis was 66 years among males (range 0 - 95 years) and 64 years among females (range 24-90 years).




Figure 3.7.1 Age-Specific Incidence Rate (AIR) for Lung Cancer in Saudi Arabia, 2012

ICD O-3	Morphology	Male	%	Female	%
8140	Adenocarcinoma, NOS	116	34.4	50	39.4
8070	Squamous cell carcinoma, NOS	62	18.4	10	7.9
8046	Non-small cell carcinoma	34	10.1	6	4.7
8041	Small cell carcinoma, NOS	32	9.5	6	4.7
8000	Neoplasm, malignant	21	6.2	13	10.2
8010	Carcinoma, NOS	16	4.7	3	2.4
8012	Large cell carcinoma, NOS	7	2.1	2	1.6
8246	Neuroendocrine carcinoma, NOS	4	1.2	4	3.1
8560	Adenosquamous carcinoma	4	1.2	4	3.1
8250	Bronchiolo-alveolar adenocarcinoma, NOS	4	1.2	7	5.5
	Others	36	10.7	22	17.3

Table 3.7.1 Morphological Distribution of Lung Cancer in Saudi Arabia, 2012




Figure 3.7.2 Stage Distribution of Lung Cancer in Saudi Arabia, 2012




Figure 3.7.4 Comparison of ASR* for Lung Cancer among Saudi with ASR in Selected Countries**

*ASR per 100,000

** Source for this information is summarized on page 51

Hodgkin Disease (C81)

There were 355 cases of Hodgkin disease accounting for 3.2% of all newly diagnosed cases in year 2012. Hodgkin disease ranked 7th among male and 8th among female. It affected 194 (54.6%) males and 161 (45.4%) females with a male to female ratio of 120:100. The ASR was 2/100,000 for males and 1.6/100,000 for females. The median age at diagnosis was 27 years (range 0-86 years) in males and 23 years (range 4-84) in females.




Figure 3.8.1 A ge-Specific Incidence Rate (AIR) for Hodgkin Disease in Saudi Arabia, 2012

ICD O-3	Morphology	Male	%	Female	%
9663	Hodgkin lymphoma, nodular sclerosis, NOS	90	46.4	101	62.7
9652	Hodgkin lymphoma, mixed cellularity, NOS	39	20.1	20	12.4
9650	Hodgkin lymphoma, NOS	30	15.5	19	11.8
9659	Hodgkin lymphoma, nodular lymphocyte predominance	15	7.7	4	2.5
9651	Hodgkin lymphoma, lymphocyte-rich	8	4.1	1	0.6
9667	Hodgkin lymphoma, nodular sclerosis, grade 2	6	3.1	5	3.1
9665	Hodgkin lymphoma, nodular sclerosis, grade 1	5	2.6	5	3.1
9664	Hodgkin lymphoma, nodular sclerosis, cellular phase	1	0.5	2	1.2
9653	Hodgkin lymphoma, lymphocyte depletion, NOS	0	0.0	2	1.2
	Others	0	0.0	2	1.2

Table 3.8.1 Morphological Distribution of Hodgkin Disease in Saudi Arabia,2012




Figure 3.8.2 Stage Distribution of Hodgkin Disease in Saudi Arabia, 2012




Figure 3.8.4 Comparison of ASR* for Hodgkin Disease among Saudi with ASR in Selected Countries**

*ASR per 100,000

** Source for this information is summarized on page 51

Corpus Uteri (C54)

There were 315 cases of corpus uteri cancer among females accounting for 5.3% of all newly diagnosed cases for females (5967) in year 2012. This cancer ranked 5th among female, with ASR was 5.4/100,000 in females. The median age at diagnosis was 61 years (range 18-105 years).




Figure 3.9.1 Age-Specific Incidence Rate (AIR) for Corpus Uteri Cancer in Saudi Arabia, 2012

ICD O-3	Morphology	Female	%
8380	Endometrioid adenocarcinoma, NOS	184	58.4
8140	Adenocarcinoma, NOS	42	13.3
8980	Carcinosarcoma, NOS	10	3.2
8441	Serous cystadenocarcinoma, NOS	9	2.9
8930	Endometrial stromal sarcoma, NOS	8	2.5
8310	Clear cell adenocarcinoma, NOS	7	2.2
8010	Carcinoma, NOS	6	1.9
8323	Mixed cell adenocarcinoma	6	1.9
8950	Mullerian mixed tumor	5	1.6
8931	Endometrial stromal sarcoma, low grade	4	1.3
	Others	34	10.8

Table 3.9.1 Morphological Distribution of Corpus Uteri Cancer in Saudi Arabia, 2012




Figure 3.9.2 Stage Distribution of Corpus Uteri Cancer in Saudi Arabia, 2012




Figure 3.9.4 Comparison of ASR* for Corpus Uteri Cancer among Saudi females with ASR in Selected Countries**

*ASR per 100,000

** Source for this information is summarized on page 51

Kidney (C64)

There were 313 cases of Kidney cancer accounting for 2.8 % of all newly diagnosed cases in year 2012. This cancer ranked 10th among male and 12th among female. It affected 190 (60.7%) males and 123 (39.3%) females with a male to female ratio of 154:100. The ASR was 2.8/100,000 for male and 1.8/100,000 for females. The median age at diagnosis was 53 years among males (range 0-95 years) and 52 years among females (range 0-91 years).




Figure 3.10.1 Age-Specific Incidence Rate (AIR) for Kidney Cancer in Saudi Arabia, 2012

ICD O-3	Morphology	Male	%	Female	%
8312	Renal cell carcinoma, NOS	102	53.7	63	51.2
8310	Clear cell adenocarcinoma, NOS	22	11.6	15	12.2
8960	Nephroblastoma, NOS	19	10.0	7	5.7
8317	Renal cell carcinoma, chromophobe type	17	8.9	16	13.0
8260	Papillary adenocarcinoma, NOS	12	6.3	2	1.6
8000	Neoplasm, malignant	5	2.6	4	3.3
8120	Transitional cell carcinoma, NOS	4	2.1	2	1.6
8318	Renal cell carcinoma, sarcomatoid	2	1.1	4	3.3
8140	Adenocarcinoma, NOS	1	0.5	0	0.0
8010	Carcinoma, NOS	1	0.5	0	0.0
	Others	5	2.7	10	8.1

Table 3.10.1 Morphological Distribution of Kidney Cancer in Saudi Arabia, 2012




Figure 3.10.2 Stage Distribution of Kidney Cancer in Saudi Arabia, 2012




Figure 3.10.4 Comparison of ASR* for Kidney Cancer among Saudis with ASR in Selected Countries**

*ASR per 100,000

** Source for this information is summarized on page 51

Sources:

- 1 - Canadian Cancer Statistics 2011. Canadian Cancer Society, Statistics Canada, Provincials/Territorial Cancer Registries, Public Health Agency of Canada.
- 2 - Cancer in Ireland 2013: Annual report of the National Cancer Registry. National Cancer Registry Ireland.
- 3 - Cancer Incidence and Mortality in Western Australia, 2010. A Report of the Western Australian Cancer Registry.
- 4 - CDC. Center for Disease Control and Prevention. Department of Health and Human Services. National Program of Cancer Registries (NPCR). 2010 Cancer Types Grouped by Race and Ethnicity. Available from: <http://apps.nccd.cdc.gov/uscs/cancersbyraceandethnicity.aspx?printfriendly=1>
- 5 - National Cancer Registration and Statistics in Korea. Cancer Incidence in Korea 2010.
- 6 - Cancer in Norway 2011. Cancer incidence, mortality, survival and prevalence in Norway.
- 7 - Singapore Cancer Registry. Interim Annual Registry Report. Trends in Cancer Incidence in Singapore 2006-2010. National Registry of Diseases Office (NRDO). Available from: https://www.nrdo.gov.sg/uploadedFiles/NRDO/Cancer_Trends_Report_06-10_final2.pdf
- 8 - The Hashemite Kingdom of Jordan Ministry of Health. Non-Communicable Diseases Directorate. Jordan Cancer Registry Cancer Incidence in Jordan 2009. Available from: <http://www.moh.gov.jo/AR/Documents/Annual%20Incidence%20of%20cancer%20in%20Jordan%202010.pdf>
- 9 - Atlas De Mortalidad Por Cancer. Argentina, 2007-2011.
- 10 - Welsh Cancer Intelligence & Surveillance Unit. Annual Publication No. SA12/01 Cancer Incidence in Wales 2006-2010. Available from: <http://www.wales.nhs.uk/sites3/Documents/242/incpub2012.pdf>
- 11 - Cancer Incidence among Nationals of the GCC States, 1998-2009.
- 12 - GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide, IARC, Lyon: International Agency for Research on Cancer. Available from: http://www-dep.iarc.fr/globocan/im_sel.HTM
- 13 - Cancer Incidence in Five Continents Vol. X, IARC. Scientific Publication, Lyon, France, 2013. Available from: <http://ci5.iarc.fr/CI5-X/ci5-X.htm>

PART IV
CANCER AMONG NON-SAUDIS
2012

Cancer among Non-Saudi Population 2012

Between January and December 2012, a total of 3,393 cancer cases were reported among the Non-Saudi population. *In situ* cases were 85 and cases were ICD-O-3 coded failed to convert to ICD-10 codes as described in the data management were 91 cases (see page 10). As a result, the total number of cases analyzed was 3,302. Out of this 1,724 (52.2%) were males and 1,578 (47.8%) were females. The male to female ratio was 109:100. Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly; the pattern of cancer had some significant differences. Those under 15 represented 19.3% of the population, those 60 years and over represented 2.5% and the 15 to 59 age-group represented 78.2% of non-Saudi population. During 2012, approximately 4.4% of all cancers occurred before the age of 15. Where 21.2 % occurred between the ages 15 to 39 years, 59.4% were between the ages 40-64, and 15.3% occurred after the age of 64. The median age at diagnosis was 52 years in males (range 0-96 years) and 47 years in females (range 0-92).

Cancer	No.	%
Breast	644	19.5
Colorectal	359	10.9
Leukaemia	195	5.9
NHL	173	5.2
Thyroid	168	5.1
Skin	163	4.9
Lung	148	4.5
Prostate	140	4.2
Other & unspecified	120	3.6
Stomach	108	3.3


Table 4.1 Ten Most Common Cancer among Non-Saudi, 2012

Nationality	Female	%	Male	%	Total	%
Yemen	245	15.5	276	16.0	521	15.8
Egypt	162	10.3	213	12.4	375	11.4
Sudan	129	8.2	161	9.3	290	8.8
Philippines	144	9.1	125	7.3	269	8.1
Syrian Arab Republic	128	8.1	130	7.5	258	7.8
Pakistan	94	6.0	139	8.1	233	7.1
India	43	2.7	105	6.1	148	4.5
Gaza Strip(Palestine	71	4.5	53	3.1	124	3.8
Jordan	61	3.9	60	3.5	121	3.7
Indonesia	80	5.1	15	0.9	95	2.9
Bangladesh	13	0.8	70	4.1	83	2.5
United States of America	23	1.5	40	2.3	63	1.9
Ethiopia	43	2.7	17	1.0	60	1.8
Somalia	28	1.8	24	1.4	52	1.6
Bahrain	35	2.2	14	0.8	49	1.5
Eritrea	28	1.8	18	1.0	46	1.4
United Kingdom	13	0.8	24	1.4	37	1.1
Chad	16	1.0	17	1.0	33	1.0
Nigeria	15	1.0	16	0.9	31	0.9
Myanmar	20	1.3	10	0.6	30	0.9
Afghanistan	17	1.1	12	0.7	29	0.9
Lebanon	9	0.6	19	1.1	28	0.8
Kuwait	16	1.0	11	0.6	27	0.8
Morocco	12	0.8	12	0.7	24	0.7
Sri Lanka	14	0.9	7	0.4	21	0.6
Canada	6	0.4	10	0.6	16	0.5
Australia	5	0.3	9	0.5	14	0.4
Occ Palestinian Terr	7	0.4	6	0.3	13	0.4
Nepal	0	0.0	12	0.7	12	0.4
Turkey	2	0.1	10	0.6	12	0.4
Mali	1	0.1	10	0.6	11	0.3
Other Nationalities	98	6.2	79	4.6	177	5.4
Total	1578	100.0	1724	100.0	3302	100.0

Table 4.2 Distribution of Cancer Cases among Different Nationalities in Order of Relative Frequency, 2012

Male 1726

Colorectal	242	14.0%
Prostate	140	8.1%
Leukaemia	120	7.0%
Lung	118	6.8%
Skin	117	6.8%
NHL	113	6.5%
Bladder	90	5.2%
Stomach	82	4.8%
Other Sites	75	4.3%
Liver	69	4.0%
Brain, CNS	58	3.4%



Female 1578

Breast	632	40.1%
Colorectal	117	7.4%
Thyroid	110	7.0%
Leukaemia	75	4.8%
Ovary	60	3.8%
NHL	60	3.8%
Cervix Uteri	57	3.6%
Corpus Uteri	55	3.5%
Skin	46	2.9%
Other Sites	45	2.9%
Brain, CNS	31	2.0%

Figure 4.1 Ten Most Common Cancer among Non-Saudi by Sex, 2012




Figure 4.2 Age-Specific Incidence Rate (AIR) for All Cancers Among Non-Saudis in Saudi Arabia, 2012

PART V

Incidence Tables

Table 5.1.1 - Number of Cancer Cases Among Saudi Males by Primary Site and Age Groups, 2012

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	4	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0.10%
C01-C02	Tongue	42	0	0	0	0	0	2	2	3	1	3	5	4	4	6	3	3	6	0.80%
C03-C06	Mouth	37	0	0	0	0	1	0	1	2	0	1	3	5	4	4	5	4	7	0.70%
C07-C08	Salivary Glands	8	0	0	0	0	0	0	1	2	0	1	0	0	1	0	0	2	1	0.20%
C09	Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0.00%
C10	Other Oropharynx	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0.10%
C11	Nasopharynx	111	0	0	0	3	2	2	1	2	8	16	19	16	15	13	5	3	6	2.20%
C12-C13	Hypopharynx	6	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	2	0	0.10%
C14	Pharynx Unspecified	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.00%
C15	Oesophagus	83	1	0	0	0	0	2	2	2	3	6	6	1	7	5	6	16	26	1.60%
C16	Stomach	186	0	0	0	0	0	1	3	3	7	4	3	21	18	20	20	30	51	3.70%
C17	Small Intestine	34	0	1	0	0	0	0	1	0	4	3	3	1	1	5	4	5	6	0.70%
C18	Colon	391	0	0	0	0	2	1	5	11	8	27	32	48	47	43	55	42	70	7.70%
C19-C20	Rectum	284	0	0	0	0	0	4	9	9	12	18	31	31	45	38	22	35	30	5.60%
C21	Anus	23	0	0	0	0	0	0	0	2	1	3	4	3	2	3	3	2	3	0.50%
C22	Liver	344	0	5	1	0	1	1	1	1	2	6	14	20	27	55	55	56	99	6.80%
C23-C24	Gallbladder etc.	68	0	0	0	0	0	1	0	2	0	1	3	6	10	9	7	13	16	1.30%
C25	Pancreas	155	0	0	0	0	0	0	3	2	8	5	11	17	20	23	13	19	33	3.10%
C30-C31	Nose, Sinuses etc.	17	0	0	0	1	0	1	0	0	1	0	1	1	4	1	2	3	3	0.30%
C32	Larynx	59	0	0	0	0	0	0	0	0	1	1	5	5	4	12	9	7	15	1.20%
C33-C34	Trachea, Bronchus, Lung	336	0	2	0	1	1	1	1	3	6	13	17	27	40	42	43	52	87	6.60%
C37-C38	Other Thoracic Organs	18	0	1	0	0	0	2	3	1	0	0	0	1	4	1	0	1	4	0.40%
C40-C41	Bone	85	0	3	9	9	20	12	4	3	2	2	3	2	5	3	2	1	5	1.70%
C43	Melanoma of Skin	8	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	2	4	0.20%
C44	Other Skin	169	0	0	0	1	2	6	10	5	9	7	7	6	7	15	15	25	54	3.30%
C45	Mesothelioma	12	0	0	0	0	0	0	1	0	0	0	0	1	0	1	2	2	5	0.20%
C46	Kaposi Sarcoma	24	0	0	0	0	0	1	0	0	0	2	2	1	1	3	4	1	9	0.50%
C47-C49	Connective, Soft Tissue	86	0	7	2	5	6	9	4	9	8	4	3	6	4	11	3	4	11	1.70%
C50	Breast	25	0	0	0	0	0	0	1	1	0	2	4	5	0	2	1	4	5	0.50%
C60	Penis	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0.10%
C61	Prostate	288	0	0	0	0	1	0	0	0	0	1	1	18	17	38	51	41	120	5.70%
C62	Testis	82	0	5	0	1	4	16	22	9	11	6	4	2	1	1	0	0	0	1.60%
C63	Other Male Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C64	Kidney	190	0	14	7	0	0	2	3	9	10	12	24	17	17	9	21	18	27	3.70%
C65	Renal Pelvis	8	0	0	0	0	0	0	0	0	0	0	1	1	2	1	2	0	1	0.20%
C66	Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0.00%
C67	Bladder	193	0	0	1	0	0	0	0	8	5	6	17	14	26	21	16	22	57	3.80%
C68	Other Urinary Organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.00%
C69	Eye	23	0	15	1	1	0	0	0	0	1	0	0	0	1	1	0	0	3	0.50%
C70-C72	Brain, Nervous System	175	0	18	15	13	9	7	5	8	9	9	15	16	13	13	8	8	9	3.50%
C73	Thyroid	193	0	0	0	1	3	6	20	14	17	24	22	21	16	16	10	13	10	3.80%
C74	Adrenal Gland	18	0	9	1	0	1	0	1	2	0	0	1	0	1	0	1	1	0	0.40%
C75	Other Endocrine	9	0	1	2	0	2	0	1	1	0	0	0	0	0	1	0	0	0	0.20%
C81	Hodgkin Disease	194	0	3	7	14	31	30	22	15	15	10	12	14	6	5	3	3	4	3.80%
C82-C85-C96	Non-Hodgkin Lymphoma	424	0	13	8	8	24	17	23	16	28	28	26	32	31	30	36	45	59	8.40%
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C90	Multiple Myeloma	71	0	0	0	0	0	1	0	3	1	5	5	4	8	9	9	12	14	1.40%
C91	Lymphoid Leukemia	229	0	67	29	36	12	10	5	3	5	3	3	6	6	10	8	8	18	4.50%
C92-C94	Myeloid Leukemia	168	0	14	11	12	13	14	16	9	4	5	11	12	8	5	12	6	16	3.30%
C95	Leukemia Unspecified	21	0	3	1	1	0	0	2	0	1	3	3	1	2	1	1	2	0	0.40%
Other	Other & Unspecified	153	0	0	0	3	2	0	2	6	4	9	11	13	15	18	13	18	39	3.00%
All	All Sites Total	5067	1	182	95	112	137	149	175	167	194	244	337	398	442	486	474	537	937	100.00%
Not C44	All Sites but C44	4898	1	182	95	111	135	143	165	162	185	237	330	392	435	471	459	512	883	96.70%

Table 5.1.2 - Number of Cancer Cases Among Saudi Females by Primary Site and Age Groups, 2012

ICD (10th)	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	0.10%
C01-C02	51	0	0	0	0	0	0	1	2	4	2	3	6	6	4	6	7	10	0.90%
C03-C06	33	0	0	0	0	0	1	1	0	1	5	4	5	3	2	3	3	5	0.60%
C07-C08	28	0	0	0	0	0	0	3	2	2	2	3	2	4	1	2	1	5	0.50%
C09	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0.00%
C10	3	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	1	0.10%
C11	45	0	0	0	1	0	2	2	6	7	6	7	6	4	3	1	0	0	0.80%
C12-C13	17	0	0	0	0	0	0	0	1	1	3	3	3	0	3	1	1	1	0.30%
C14	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0.00%
C15	63	0	0	0	0	0	0	4	1	2	4	1	5	3	3	11	6	23	1.10%
C16	94	0	0	0	0	3	4	3	7	5	7	6	7	7	7	11	15	12	1.60%
C17	25	0	0	0	0	0	0	3	1	0	2	1	2	5	3	3	2	3	0.40%
C18	324	0	0	0	0	1	0	3	11	16	21	30	50	41	42	34	34	41	5.40%
C19-C20	231	0	0	0	0	1	1	5	5	8	28	29	30	18	23	20	19	44	3.90%
C21	9	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	1	4	0.20%
C22	130	0	6	1	0	1	0	2	2	1	4	4	9	9	20	20	22	29	2.20%
C23-C24	90	0	0	0	0	0	2	2	0	2	2	6	8	11	10	13	13	21	1.50%
C25	87	0	0	1	0	0	0	2	2	2	1	5	7	12	11	10	9	25	1.50%
C30-C31	13	0	0	0	0	0	0	0	0	1	1	0	2	1	3	0	1	3	0.20%
C32	12	0	0	0	0	0	0	0	0	0	0	1	3	2	0	2	1	3	0.20%
C33-C34	127	0	0	0	0	0	1	3	2	0	5	6	17	15	16	18	12	32	2.10%
C37-C38	10	0	1	1	0	1	1	1	0	1	1	0	0	0	0	1	0	2	0.20%
C40-C41	60	0	2	3	18	10	1	2	3	0	3	1	2	5	2	3	2	3	1.00%
C43	16	0	0	0	1	0	0	0	1	0	1	3	0	0	2	2	2	4	0.30%
C44	132	0	0	1	1	2	3	5	7	5	6	4	11	9	15	17	12	34	2.20%
C45	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.00%
C46	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0.00%
C47-C49	59	0	8	8	3	5	1	5	4	5	3	3	3	0	3	5	0	3	1.00%
C50	1542	1	0	0	0	0	3	61	85	157	209	265	239	168	109	95	77	73	25.80%
C51	8	0	0	0	1	0	0	0	0	0	0	3	0	0	1	0	0	3	0.10%
C52	4	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	0.10%
C53	137	0	0	0	0	0	0	2	4	14	13	26	16	24	10	7	9	12	2.30%
C54	315	0	0	0	0	1	3	3	3	12	16	23	33	53	34	53	42	39	5.30%
C55	48	0	0	0	0	0	1	1	0	3	5	5	2	5	4	2	14	6	0.80%
C56	193	0	0	1	2	7	5	8	11	4	17	24	20	17	12	26	18	21	3.20%
C57	15	0	0	0	0	0	1	0	1	1	2	1	0	0	2	2	4	1	0.30%
C58	3	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0.10%
C64	123	0	9	2	0	1	1	7	1	6	12	14	19	14	13	11	5	8	2.10%
C65	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C66	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C67	52	0	0	0	0	1	0	0	0	0	3	5	6	5	7	7	6	12	0.90%
C68	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.00%
C69	19	0	16	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	0.30%
C70-C72	123	0	11	18	10	3	6	3	10	8	8	11	8	9	7	5	1	5	2.10%
C73	697	0	0	2	8	23	54	75	85	104	93	73	47	35	42	23	14	19	11.70%
C74	17	0	10	2	0	0	0	1	1	1	0	0	1	0	0	0	0	0	0.30%
C75	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C81	161	0	4	6	11	36	27	25	10	11	2	4	6	6	4	3	4	2	2.70%
C82-C85:C96	316	0	3	8	12	8	13	16	15	15	17	23	32	34	22	28	35	35	5.30%
C88	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.00%
C90	52	0	0	0	0	0	0	0	1	1	3	5	5	9	3	8	9	8	0.90%
C91	132	0	40	21	17	8	5	5	3	2	3	3	6	4	4	1	4	6	2.20%
C92-C94	171	0	16	4	9	11	12	10	15	17	15	14	13	7	10	5	6	7	2.90%
C95	25	0	4	3	2	2	2	1	1	0	1	3	1	0	0	1	2	2	0.40%
Other	140	0	5	1	0	1	2	3	3	4	7	14	16	11	20	14	12	27	2.30%
All	5967	1	135	83	96	128	155	268	307	426	537	638	649	560	478	479	427	600	100.00%
Not C44	5835	1	135	82	95	126	152	263	300	421	531	634	638	551	463	462	415	566	97.80%

Table 5.1.3 - Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site and Age Groups, 2012

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	4	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	1.5	0	0.8	0	0.1
C01-C02	Tongue	42	0	0	0	0	0	0.2	0.2	0.4	0.2	0.6	1.1	1.1	1.5	3.2	2.2	3.3	4.9	0.4	0.6
C03-C06	Mouth	37	0	0	0	0	0.1	0	0.1	0.3	0	0.2	0.7	1.4	1.5	2.1	3.7	4.4	5.7	0.4	0.6
C07-C08	Salivary Glands	8	0	0	0	0	0	0	0.1	0.3	0	0.2	0	0	0.4	0	0	2.2	0.8	0.1	0.1
C09	Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0	0.8	0	0
C10	Other Oropharynx	4	0	0	0	0	0	0	0	0	0	0	0	0	0.8	0	0.7	1.1	0	0	0.1
C11	Nasopharynx	111	0	0	0	0.3	0.2	0.2	0.1	0.3	1.2	3	4.3	4.6	5.6	6.8	3.7	3.3	4.9	1.1	1.6
C12-C13	Hypopharynx	6	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0.5	0.7	2.2	0.8	0.1	0.1
C14	Pharynx Unspecified	1	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0
C15	Oesophagus	83	1	0	0	0	0	0.2	0.2	0.3	1.1	1.4	1.4	0.3	2.6	2.6	4.4	17.8	21.1	0.8	1.4
C16	Stomach	186	0	0	0	0	0	0.1	0.3	0.4	1.1	0.7	1.8	6	6.8	10.5	14.8	33.3	41.4	1.9	3.2
C17	Small Intestine	34	0	0.1	0	0	0	0	0.1	0	0.6	0.6	0	0.3	0.4	2.6	3	5.6	4.9	0.3	0.6
C18	Colon	391	0	0	0	0	0.2	0.1	0.6	1.4	1.2	5	7.2	13.7	17.7	22.6	40.6	46.6	56.9	3.9	6.5
C19-C20	Rectum	284	0	0	0	0	0	0.4	1	1.2	1.9	3.3	7	8.8	16.9	20	16.2	38.9	24.4	2.8	4.6
C21	Anus	23	0	0	0	0	0	0	0	0.3	0.2	0	0.9	0.9	0.8	1.6	1.5	3.3	2.4	0.2	0.4
C22	Liver	344	0	0.4	0.1	0	0.1	0.1	0.1	0.3	1.1	0.2	0	0.2	1.5	28.9	40.6	62.2	80.5	3.4	6.3
C23-C24	Gallbladder etc.	68	0	0	0	0	0	0.1	0	0.3	1.2	0.9	2.5	4.8	7.5	12.1	9.6	21.1	26.8	1.6	2.6
C25	Pancreas	155	0	0	0	0.1	0	0.3	0.3	0.3	1.2	0.9	0.2	0.2	0.2	0.5	1.5	3.3	2.4	0.2	0.3
C30-C31	Nose, Sinuses etc.	17	0	0	0	0.1	0	0.1	0	0	0.2	0	0.2	0	0.2	0.5	1.5	3.3	2.4	0.2	0.3
C32	Larynx	59	0	0	0	0	0	0	0	0	0.2	0.2	1.1	1.4	1.5	6.3	6.6	7.8	12.2	0.6	1.1
C33-C34	Trachea, Bronchus, Lung	336	0	0.2	0	0.1	0.1	0.1	0.1	0.4	0.9	2.4	3.8	7.7	15	22.1	31.7	57.7	70.7	3.4	5.9
C37-C38	Other Thoracic Organs	18	0	0.1	0	0	0	0.2	0.3	0.1	0	0	0	0.3	1.5	0.5	0	1.1	3.3	0.2	0.2
C40-C41	Bone	85	0	0.2	0.8	0.8	1.9	1.2	0.5	0.4	0.3	0.4	0.7	0.6	1.9	1.6	1.5	1.1	4.1	0.9	0.9
C43	Melanoma of Skin	8	0	0	0	0	0	0	0.1	0.1	0.2	0	0	0	0	0	0	2.2	3.3	0.1	0.1
C44	Other Skin	169	0	0	0	0.1	0.2	0.6	1.2	0.7	1.4	1.3	1.6	1.7	2.6	7.9	11.1	27.8	43.9	1.7	2.7
C45	Mesothelioma	12	0	0	0	0	0	0	0.1	0	0	0	0	0.3	0	0.5	1.5	2.2	4.1	0.1	0.2
C46	Kaposi Sarcoma	24	0	0	0	0	0	0.1	0	0	0	0.4	0.5	0.3	0.4	1.6	3	1.1	7.3	0.2	0.4
C47; C49	Connective, Soft Tissue	86	0	0.5	0.2	0.5	0.6	0.9	0.5	1.2	1.2	0.7	0.7	1.7	1.5	0.5	2.2	4.4	8.9	0.9	1
C50	Breast	25	0	0	0	0	0	0	0.1	0.1	0	0.4	0.9	1.4	0	1.1	0.7	4.4	4.1	0.3	0.4
C60	Penis	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	2.2	0	0	0.1
C61	Prostate	288	0	0	0	0	0.1	0	0	0	0	0.2	0.2	0.2	0.4	20	37.6	45.5	97.5	2.9	5.3
C62	Testis	82	0	0.4	0	0.1	0.4	1.7	2.5	1.2	1.7	1.1	0.9	0.6	0.4	0.5	0	0	0	0.8	0.8
C63	Other Male Genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C64	Kidney	190	0	1.1	0.6	0	0	0.2	0.3	1.2	1.5	2.2	5.4	4.8	6.4	4.7	15.5	20	21.9	1.9	2.8
C65	Renal Pelvis	8	0	0	0	0	0	0	0	0	0	0	0.2	0.3	0.8	0.5	1.5	0	0.8	0.1	0.1
C66	Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.2	0	0	0
C67	Bladder	193	0	0	0.1	0	0	0	0	1.1	0.8	1.1	3.8	4	9.8	11	11.8	24.4	46.3	1.9	3.2
C68	Other Urinary Organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	0	0
C69	Eye	23	0	1.2	0.1	0.1	0	0	0	0	0.2	0	0	0	0.4	0.5	0	0	2.4	0.2	0.3
C70-C72	Brain, Nervous System	175	0	1.4	1.3	1.2	0.9	0.7	0.6	1.1	1.4	1.7	3.4	4.6	4.9	6.8	5.9	8.9	7.3	1.8	2.2
C73	Thyroid	193	0	0	0.1	0.1	0.3	0.6	2.3	1.8	2.6	4.5	5	6	6	8.4	7.4	14.4	8.1	1.9	2.7
C74	Adrenal Gland	18	0	0.7	0.1	0.1	0.1	0	0.1	0.3	0	0	0.2	0	0.4	0	0.7	1.1	0	0.2	0.2
C75	Other Endocrine	9	0	0.1	0.2	0.1	0.2	0	0.1	0.1	0	0	0	0	0	0.5	0	0	0	0.1	0.1
C81	Hodgkin Disease	194	0	0.2	0.6	1.3	3	3.1	2.5	2	2.3	1.9	2.7	4	2.3	2.6	2.2	3.3	3.3	1.9	2
C82-C85; C96	Non-Hodgkin Lymphoma	424	0	1	0.7	0.7	2.3	1.8	2.7	2.1	4.3	5.2	5.9	9.1	11.7	15.8	26.6	50	47.9	4.2	6.2
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	71	0	0	0	0	0	0.1	0	0.4	0.2	0.9	1.1	1.1	3	4.7	6.6	13.3	11.4	0.7	1.2
C91	Lymphoid Leukemia	229	0	5.3	2.4	3.3	1.2	1	0.6	0.4	0.8	0.6	0.7	1.7	2.3	5.3	5.9	8.9	14.6	2.3	2.6
C92-C94	Myeloid Leukemia	168	0	1.1	0.9	1.1	1.2	1.4	1.8	1.2	0.6	0.9	2.5	3.4	3	2.6	8.9	6.7	13	1.7	2.1
C95	Leukemia Unspecified	21	0	0.2	0.1	0.1	0	0	0.2	0	0.2	0.6	0.7	0.3	0.8	0.5	0.7	2.2	0	0.2	0.3
Other	Other & Unspecified	153	0	0	0.3	0.2	0.2	0	0.2	0.8	0.6	1.7	2.5	3.7	5.6	9.5	9.6	20	31.7	1.5	2.5
All	All Sites Total	5067	1	14	8	10	13	15	20	22	30	45	76	113	166	255	350	596	761	50.8	78.1
Not C44	All Sites but C44	4898	1	14	8	10	13	15	19	21	29	44	75	112	164	247	339	588	718	49.1	75.3

Table 5.1.4 - Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site and Age Groups, 2012

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.5	0	1.6	0	0.1
C01-C02	Tongue	51	0	0	0	0	0	0	0.1	0.3	0.6	0.4	0.7	1.8	2.4	2.2	4.4	7.4	8	0.5	0.8
C03-C06	Mouth	33	0	0	0	0	0	0.1	0.1	0	0.2	0.9	0.9	1.5	1.2	1.1	2.2	3.2	4	0.3	0.5
C07-C08	Salivary Glands	28	0	0	0	0	0.1	0	0.3	0.3	0.3	0.4	0.7	0.6	1.6	0.5	1.5	1.1	4	0.3	0.4
C09	Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	1.1	0	0	0
C10	Other Oropharynx	3	0	0	0	0	0	0	0	0	0.2	0.2	0	0	0	0	0	0	0.8	0	0
C11	Nasopharynx	45	0	0	0	0.1	0	0.2	0.2	0.8	1.1	1.1	1.6	1.8	1.6	1.6	0.7	0	0	0.5	0.6
C12-C13	Hypopharynx	17	0	0	0	0	0	0	0	0.1	0.2	0.6	0.7	0.9	0.4	1.6	0	1.1	0.8	0.2	0.3
C14	Pharynx Unspecified	2	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0.7	0	0	0	0
C15	Oesophagus	63	0	0	0	0	0	0	0.5	0.1	0.3	0.7	0.2	1.5	1.2	1.6	8.1	6.3	18.5	0.6	1
C16	Stomach	94	0	0	0	0.3	0.4	0.4	0.3	0.9	0.8	1.3	1.4	2.1	2.7	3.8	8.1	15.8	9.6	0.9	1.5
C17	Small Intestine	25	0	0	0	0	0	0.3	0.1	0.3	0	0.4	0.2	0.6	2	1.6	2.2	2.1	2.4	0.3	0.4
C18	Colon	324	0	0	0	0.1	0.1	0	0.3	1.4	2.4	3.9	6.9	14.9	16.1	22.7	24.9	35.7	32.9	3.3	5.3
C19-C20	Rectum	231	0	0	0	0.1	0.1	0.1	0.6	0.6	1.2	5.2	6.7	8.9	7.1	12.4	14.7	20	35.3	2.3	3.7
C21	Anus	9	0	0	0	0	0	0	0	0	0	0.2	0	0	0.4	0	1.5	1.1	3.2	0.1	0.2
C22	Liver	130	0	0.5	0.1	0	0.1	0	0.2	0.3	0.2	0.7	0.9	2.7	3.5	10.8	14.7	23.1	23.3	1.3	2.3
C23-C24	Gallbladder etc.	90	0	0	0	0	0.2	0	0.2	0	0.3	0.4	1.4	2.4	4.3	5.4	9.5	16.8	9.9	1.6	1.6
C25	Pancreas	87	0	0	0.1	0	0	0.2	0.2	0.3	0.3	0.2	1.2	2.1	4.7	5.9	7.3	9.5	20.1	0.9	1.5
C30-C31	Nose, Sinuses etc.	13	0	0	0	0.1	0	0	0	0	0.2	0.2	0	0.6	0.4	1.6	0	1.1	2.4	0.1	0.2
C32	Larynx	12	0	0	0	0	0	0	0	0	0	0	0.2	0.9	0.8	0	1.5	1.1	2.4	0.1	0.2
C33-C34	Trachea, Bronchus, Lung	127	0	0	0	0	0.1	0.1	0.3	0.3	0	0.9	1.4	5.1	5.9	8.7	13.2	25.7	1.3	2.2	2.2
C37-C38	Other Thoracic Organs	10	0	0.1	0.1	0	0.1	0.1	0.1	0	0.2	0.2	0	0	0	0	0.7	0	1.6	0.1	0.1
C40-C41	Bone	60	0	0.2	0.3	1.7	1	0.1	0.2	0.4	0	0.6	0.2	0.6	2	1.1	2.2	2.1	2.4	0.6	0.7
C43	Melanoma of Skin	16	0	0	0	0	0.1	0	0	0.1	0	0.2	0.7	0	0	1.1	1.5	2.1	3.2	0.2	0.3
C44	Other Skin	132	0	0	0.1	0.1	0.2	0.3	0.6	0.9	0.8	1.1	0.9	3.3	3.5	8.1	12.5	12.6	27.3	1.3	2.1
C45	Mesothelioma	2	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0.7	0	0	0	0
C46	Kaposi Sarcoma	2	0	0	0	0	0	0	0	0	0	0	0.2	0	0.4	0	0	0	0	0	0
C47-C49	Connective, Soft Tissue	59	0	0.7	0.7	0.3	0.5	0.1	0.6	0.5	0.8	0.6	0.7	0.9	0	1.6	3.7	0	2.4	0.6	0.7
C50	Breast	1542	1	0	0	0	0.3	0.3	6.9	11	24	39	61.4	71.2	65.8	58.9	69.7	80.9	58.6	15.6	22.1
C51	Vulva	8	0	0	0.1	0	0	0	0	0	0	0	0.7	0	0	0.5	0	0	2.4	0.1	0.1
C52	Vagina	4	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0.5	0	1.1	0.8	0	0.1
C53	Cervix Uteri	137	0	0	0	0	0	0	0.2	0.5	2.1	2.4	6	4.8	9.4	5.4	5.1	9.5	9.6	1.4	2.1
C54	Corpus Uteri	315	0	0	0	0.1	0.3	0.3	0.3	0.4	1.8	3	5.3	9.8	20.8	18.4	38.9	44.2	31.3	3.2	5.4
C55	Uterus Unspecified	48	0	0	0	0	0	0.1	0.1	0	0.5	0.9	1.2	0.6	2	2.2	1.5	14.7	4.8	0.5	0.8
C56	Ovary	193	0	0	0.1	0.2	0.7	0.5	0.9	1.4	0.6	3.2	5.6	6	6.7	6.5	19.1	18.9	16.8	2	3
C57	Other Female Genital	15	0	0	0	0	0.1	0.1	0	0.1	0.2	0.4	0.2	0	0	1.1	1.5	4.2	0.8	0.2	0.2
C58	Placenta	3	0	0	0	0	0	0.1	0	0	0.2	0.2	0	0	0	0	0	0	0	0	0
C64	Kidney	123	0	0.7	0.2	0	0.1	0.1	0.8	0.1	0.9	2.2	3.2	5.7	5.5	7	8.1	5.3	6.4	1.2	1.8
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C67	Bladder	52	0	0	0	0	0.1	0	0	0	0	0.6	1.2	1.8	2	3.8	5.1	6.3	9.6	0.5	0.9
C68	Other Urinary Organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	0	0
C69	Eye	19	0	1.3	0	0	0	0	0	0	0	0.2	0	0.3	0	0	0	0	0.8	0.2	0.2
C70-C72	Brain, Nervous System	123	0	0.9	1.6	0.9	0.3	0.6	0.3	1.3	1.2	1.5	2.5	2.4	3.5	3.8	3.7	1.1	4	1.2	1.5
C73	Thyroid	697	0	0.2	0.7	2.2	2.2	5.5	8.5	11	15.9	17.3	16.9	14	13.7	22.7	16.9	14.7	15.2	7	8.3
C74	Adrenal Gland	17	0	0.8	0.2	0	0	0.1	0.1	0.1	0.2	0	0.2	0	0	0	0	0	0	0.2	0.2
C75	Other Endocrine	1	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0
C81	Hodgkin Disease	161	0	0.3	0.5	1	3.4	2.7	2.8	1.3	1.7	0.4	0.9	1.8	2.4	2.2	2.2	4.2	1.6	1.6	1.6
C82-C85:C96	Non-Hodgkin Lymphoma	316	0	0.2	0.7	1.1	0.8	1.3	1.8	1.9	2.3	3.2	5.3	9.5	13.3	11.9	20.5	36.8	28.1	3.2	4.7
C88	Immunoproliferative Disease	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	0	0
C90	Multiple Myeloma	52	0	0	0	0	0	0	0	0.1	0.2	0.6	1.2	1.5	3.5	1.6	5.9	9.5	6.4	0.5	0.9
C91	Lymphoid Leukemia	132	0	3.3	1.8	1.6	0.8	0.5	0.6	0.4	0.3	0.6	0.7	1.8	1.6	2.2	0.7	4.2	4.8	1.3	1.4
C92-C94	Myeloid Leukemia	171	0	1.3	0.4	0.8	1	1.2	1.1	1.9	2.6	2.8	3.2	3.9	2.7	5.4	3.7	6.3	5.6	1.7	2.1
C95	Leukemia Unspecified	25	0	0.3	0.3	0.2	0.2	0.2	0.1	0.1	0	0.2	0.7	0.3	0	0	0.7	2.1	1.6	0.3	0.3
Other	Other & Unspecified	140	0	0.4	0.1	0	0.1	0.2	0.3	0.4	0.6	1.3	3.2	4.8	4.3	10.8	10.3	12.6	21.7	1.4	2.3
All	All sites Total	5967	1	11	7	9	12	16	30	40	65	100	148	193	219	258	351	449	481	60.3	86.7
Not C44	All sites but C44	5835	1	11	7	9	12	15	30	39	64	99	147	190	216	250	339	436	454	59	84.6

Table 5.4.1 - Number of Cancer Cases Among Non-Saudi Males by Primary Site and Age Groups, 2012

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	4	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0.20%
C01-C02	Tongue	23	0	0	0	0	0	1	0	1	2	3	3	3	5	3	0	2	0	1.30%
C03-C06	Mouth	18	0	0	0	0	0	1	0	2	2	2	6	2	1	1	0	1	0	1.00%
C07-C08	Salivary Glands	13	0	0	1	0	0	3	2	1	2	1	0	2	0	1	0	0	0	0.80%
C09	Tonsil	3	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	0	0.20%
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C11	Nasopharynx	36	0	0	0	0	0	1	2	3	3	5	5	8	4	4	0	1	0	2.10%
C12-C13	Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C14	Pharynx Unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%
C15	Oesophagus	24	0	0	0	0	0	1	0	3	0	2	2	3	3	2	5	1	2	1.40%
C16	Stomach	82	0	0	0	0	1	0	0	7	7	7	10	16	13	8	4	5	4	4.80%
C17	Small Intestine	12	0	0	0	0	1	0	0	0	0	1	2	2	2	1	1	2	1	0.70%
C18	Colon	147	0	0	0	0	0	1	5	11	8	15	19	21	21	16	17	10	4	8.50%
C19-C20	Rectum	95	0	0	0	0	1	1	5	2	7	7	11	14	19	11	7	5	4	5.50%
C21	Anus	9	0	0	0	0	1	0	0	0	0	1	4	1	0	2	0	0	0	0.50%
C22	Liver	69	0	3	0	0	0	2	2	2	2	1	7	7	19	14	5	2	5	4.00%
C23-C24	Gallbladder etc.	18	0	0	0	0	0	0	0	1	1	2	2	7	2	2	1	0	0	1.00%
C25	Pancreas	23	0	0	0	0	0	0	0	0	1	0	6	2	5	2	4	2	1	1.30%
C30-C31	Nose, Sinuses etc.	4	0	0	0	0	0	0	0	1	1	0	2	0	0	0	0	0	0	0.20%
C32	Larynx	32	0	0	0	0	0	0	0	0	4	2	9	3	6	5	1	0	2	1.90%
C33-C34	Trachea, Bronchus, Lung	118	0	0	0	0	0	0	2	3	4	6	10	24	25	20	8	4	12	6.80%
C37-C38	Other Thoracic Organs	7	0	0	0	0	0	0	1	1	1	0	0	1	0	1	0	1	1	0.40%
C40-C41	Bone	13	0	0	0	1	0	2	1	3	0	0	2	0	1	1	2	0	0	0.80%
C43	Melanoma of Skin	6	0	0	0	0	0	0	0	0	0	2	0	2	1	0	1	0	0	0.30%
C44	Other Skin	116	1	0	0	0	0	5	3	6	4	10	13	20	19	16	11	4	4	6.70%
C45	Mesothelioma	8	0	0	0	0	0	0	2	1	0	0	0	2	2	1	0	0	0	0.50%
C46	Kaposi Sarcoma	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0.10%
C47-C49	Connective, Soft Tissue	31	0	3	2	1	0	2	0	3	2	3	5	0	2	3	2	1	1	1.80%
C50	Breast	12	0	0	0	0	0	0	1	1	0	0	3	4	1	2	0	0	0	0.70%
C60	Penis	4	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	1	0.20%
C61	Prostate	140	0	1	0	0	0	0	0	0	0	2	5	10	30	38	24	17	13	8.10%
C62	Testis	20	0	0	0	0	0	0	4	8	1	2	1	2	1	1	0	0	0	1.20%
C63	Other Male Genital	1	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	0	0	0.10%
C64	Kidney	50	0	2	0	0	0	0	1	0	1	6	10	9	9	4	6	0	2	2.90%
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C67	Bladder	90	0	1	0	0	0	1	1	2	2	7	11	16	20	11	6	4	8	5.20%
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C69	Eye	3	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1	0.20%
C70-C72	Brain, Nervous System	58	0	1	1	4	0	3	2	3	2	4	7	9	14	4	3	1	0	3.40%
C73	Thyroid	57	1	0	0	0	0	4	8	5	6	5	10	14	2	1	0	0	1	3.30%
C74	Adrenal Gland	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%
C75	Other Endocrine	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%
C81	Hodgkin Disease	46	0	0	2	4	5	4	3	5	3	7	3	3	3	3	0	1	0	2.70%
C82-C85;C96	Non-Hodgkin Lymphoma	113	0	1	3	2	5	2	9	8	9	12	13	15	13	9	5	4	3	6.60%
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C90	Multiple Myeloma	19	0	0	0	0	0	0	1	1	1	3	2	4	3	0	1	1	2	1.10%
C91	Lymphoid Leukemia	50	0	10	10	1	5	5	4	5	1	2	1	1	1	2	0	1	1	2.90%
C92-C94	Myeloid Leukemia	57	0	2	2	0	0	0	8	7	4	6	6	5	9	5	3	0	0	3.30%
C95	Leukemia Unspecified	13	0	0	1	1	0	1	0	0	1	1	1	2	1	0	2	2	0	0.80%
Other	Other & Unspecified	75	0	1	0	1	0	1	1	2	8	11	9	22	10	4	2	0	3	4.40%
All	All Sites Total	1724	2	26	23	15	19	39	69	98	92	140	203	260	271	198	120	73	76	100.00%
Not C44	All Sites but C44	1608	1	26	23	15	19	34	66	92	88	130	190	240	252	182	109	69	72	93.30%

Table 5.4.2 - Number of Cancer Cases Among Non-Saudi Females by Primary Site and Age Groups, 2012

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C01-C02	Tongue	8	0	0	0	0	0	0	0	1	0	0	1	0	1	0	1	2	2	0.50%
C03-C06	Mouth	4	0	0	0	0	0	1	0	0	0	1	0	0	0	0	2	0	0	0.30%
C07-C08	Salivary Glands	8	0	0	0	0	2	1	0	2	0	2	0	1	0	0	0	0	0	0.50%
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C11	Nasopharynx	8	0	0	0	0	1	0	0	1	1	1	2	1	1	0	0	0	0	0.50%
C12-C13	Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C14	Pharynx Unspecified	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0.10%
C15	Oesophagus	10	0	0	0	0	0	0	0	1	0	1	1	3	1	2	0	1	0	0.60%
C16	Stomach	26	0	0	0	0	0	0	1	1	4	1	5	1	4	2	3	2	2	1.60%
C17	Small Intestine	8	0	0	0	0	0	0	0	2	0	0	1	0	2	2	0	1	0	0.50%
C18	Colon	80	0	0	0	0	1	0	2	3	7	10	11	16	10	7	7	7	6	5.10%
C19-C20	Rectum	37	0	0	0	0	0	1	2	4	3	4	3	5	6	3	4	1	1	2.30%
C21	Anus	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.10%
C22	Liver	18	0	2	0	0	0	0	0	1	2	0	1	1	4	1	3	1	2	1.10%
C23-C24	Gallbladder etc.	11	0	0	0	0	1	0	0	2	0	0	0	0	2	0	0	4	2	0.70%
C25	Pancreas	18	0	0	0	0	0	0	0	0	1	1	1	3	3	3	2	3	1	1.10%
C30-C31	Nose, Sinuses etc.	6	0	0	0	0	0	0	0	1	0	1	0	1	0	1	1	1	0	0.40%
C32	Larynx	5	0	0	0	0	0	0	0	0	1	1	0	0	0	0	2	1	0	0.30%
C33-C34	Trachea, Bronchus, Lung	30	0	0	0	0	0	0	1	0	3	2	5	0	6	5	1	5	2	1.90%
C37-C38	Other Thoracic Organs	2	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0.10%
C40-C41	Bone	11	0	0	2	3	1	2	1	1	1	0	0	0	0	0	0	0	0	0.70%
C43	Melanoma of Skin	4	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0.30%
C44	Other Skin	46	0	0	0	0	0	0	0	1	0	8	11	6	6	5	5	3	1	2.90%
C45	Mesothelioma	2	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0.10%
C46	Kaposi Sarcoma	2	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.10%
C47-C49	Connective, Soft Tissue	11	0	1	0	0	0	0	0	2	0	1	5	0	1	0	1	0	0	0.70%
C50	Breast	632	0	0	0	1	0	6	17	41	74	110	117	91	68	33	27	22	25	40.10%
C51	Vulva	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0.10%
C52	Vagina	4	0	1	0	1	0	0	0	0	0	0	1	0	0	0	1	0	0	0.30%
C53	Cervix Uteri	57	0	0	0	0	0	0	1	3	8	10	10	14	4	1	3	2	1	3.60%
C54	Corpus Uteri	55	0	0	0	0	0	0	2	1	3	5	5	8	12	5	9	3	2	3.50%
C55	Uterus Unspecified	4	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0	0	0	0.30%
C56	Ovary	60	0	0	1	2	0	1	5	5	5	10	13	4	7	3	2	0	2	3.80%
C57	Other Female Genital	6	0	0	0	0	1	0	0	0	0	1	0	1	0	3	0	0	0	0.40%
C58	Placenta	2	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.10%
C64	Kidney	21	0	1	0	0	0	1	0	2	1	0	4	6	0	3	3	0	0	1.30%
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0.10%
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C67	Bladder	12	0	0	0	0	0	0	0	0	1	0	0	2	0	3	3	1	2	0.80%
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C69	Eye	4	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.30%
C70-C72	Brain, Nervous System	31	0	4	5	1	2	2	3	0	1	2	6	2	1	2	0	0	0	2.00%
C73	Thyroid	110	0	0	0	1	3	5	16	19	21	12	10	10	6	2	1	2	2	7.00%
C74	Adrenal Gland	2	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0.10%
C75	Other Endocrine	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.10%
C81	Hodgkin Disease	22	0	0	1	2	4	4	4	1	2	1	0	1	1	0	1	0	0	1.40%
C82-C85;C96	Non-Hodgkin Lymphoma	60	0	2	1	2	1	4	2	3	7	5	2	5	8	5	5	3	5	3.80%
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C90	Multiple Myeloma	13	0	0	0	0	0	0	0	0	0	2	0	2	3	2	3	0	1	0.80%
C91	Lymphoid Leukemia	36	0	14	10	2	1	1	2	1	0	1	0	0	1	0	0	1	2	2.30%
C92-C94	Myeloid Leukemia	32	0	2	0	1	3	2	4	3	1	2	4	2	3	2	0	1	2	2.00%
C95	Leukemia Unspecified	7	0	3	1	0	0	0	0	0	0	0	0	2	0	0	0	0	1	0.40%
Other	Other & Unspecified	45	0	0	0	0	0	1	4	3	3	4	7	4	6	5	2	3	3	2.90%
All	All Sites Total	1578	0	34	22	17	21	34	69	106	153	204	227	194	168	95	94	72	68	100.00%
Not C44	All Sites but C44	1532	0	34	22	17	21	34	69	105	153	196	216	188	162	90	89	69	67	97.10%

Table 5.4.3 - Age-Specific Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Non-Saudi Males (per 100,000) by Primary Site and Age Groups, 2012

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	4	0	0	0	0	0	0	0	0	0	0.1	0.1	0.2	0.4	0	0	0	0	0.1	0
C01-C02	Tongue	23	0	0	0	0	0	0.4	0	0.1	0.2	0.3	0.4	0.7	2.1	2.8	0	12.2	0	0.3	0.6
C03-C06	Mouth	18	0	0	0	0	0	0.4	0	0.2	0.2	0.3	0.9	0.5	0.4	0.9	0	6.1	0	0.3	0.3
C07-C08	Salivary Glands	13	0	0	0.3	0	0	1.3	0.4	0.1	0.2	0.1	0	0.5	0	0.9	0	0	0	0.2	0.2
C09	Tonsil	3	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0.4	0	0	0	0	0	0
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	36	0	0	0	0	0	0.4	0.4	0.3	0.3	0.5	0.7	1.9	1.7	3.7	0	6.1	0	0.5	0.6
C12-C13	Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C14	Pharynx Unspecified	1	0	0	0	0	0	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Oesophagus	24	0	0	0	0	0	0	0	0.3	0.1	0.2	0.3	0.7	1.2	1.9	13.9	6.1	12.5	0.4	1
C16	Stomach	82	0	0	0	0	0.4	0	0	0.7	0.6	0.7	1.5	3.8	5.4	7.4	11.1	30.5	24.9	1.2	2.4
C17	Small Intestine	12	0	0	0	0	0.4	0	0	0	0	0.1	0.3	0.5	0.8	0.9	0	12.2	6.2	0.2	0.5
C18	Colon	147	0	0	0	0	0.4	0	1	1.1	0.6	1.6	2.8	4.9	8.7	14.8	47.1	61.1	24.9	2.2	4.8
C19-C20	Rectum	95	0	0	0	0	0.4	0.4	1	0.2	0.7	0.7	1.6	3.3	7.9	10.2	19.4	30.5	24.9	1.4	2.9
C21	Anus	9	0	0	0	0.4	0	0	0	0	0	0.1	0.6	0.2	0	1.9	0	0	0	0.1	0.2
C22	Liver	69	0	0	0	0	0	0	0.4	0.2	0.2	0.1	1	1.6	7.9	13	13.9	12.2	31.1	1	2.4
C23-C24	Gallbladder etc.	18	0	0	0	0	0	0	0	0.1	0.1	0.2	0.3	1.6	0.8	1.9	2.8	0	0	0.3	0.3
C25	Pancreas	23	0	0	0	0	0	0	0	0	0.1	0	0.9	0.5	2.1	1.9	11.1	12.2	6.2	0.3	0.9
C30-C31	Nose, Sinuses etc.	4	0	0	0	0	0	0	0	0.1	0.1	0	0.3	0	0	0	0	0	0	0.1	0
C32	Larynx	32	0	0	0	0	0	0	0	0.3	0.3	0.2	1.3	0.7	2.5	4.6	2.8	0	12.5	0.5	0.8
C33-C34	Trachea, Bronchus, Lung	118	0	0	0	0	0	0	0.4	0.3	0.3	0.6	1.5	5.6	10.3	18.5	22.2	24.4	74.7	1.8	4.3
C37-C38	Other Thoracic Organs	7	0	0	0	0	0	0	0.2	0.1	0.1	0	0	0.2	0	0.9	0	6.1	6.2	0.1	0.3
C40-C41	Bone	13	0	0	0	0.3	0	0.8	0.2	0.3	0	0	0.3	0	0.4	0.9	5.5	0	0	0.2	0.4
C43	Melanoma of Skin	6	0	0	0	0	0	0	0	0	0	0.2	0	0.5	0.4	0	2.8	0	0	0.1	0.1
C44	Other Skin	116	1	0	0	0	2.1	0	0.6	0.6	0.3	1.1	1.9	4.7	7.9	14.8	30.5	24.4	24.9	1.8	3.5
C45	Mesothelioma	8	0	0	0	0	0	0	0.4	0.1	0	0	0	0.5	0.8	0.9	0	0	0	0.1	0.1
C46	Kaposi Sarcoma	2	0	0	0	0	0	0	0	0	0	0	0.1	0.2	0	0	0	0	0	0	0
C47-C49	Connective, Soft Tissue	31	0	0.9	0.6	0.3	0	0.8	0.2	0.3	0.2	0.3	0.7	0	0.8	2.8	5.5	6.1	6.2	0.5	0.9
C50	Breast	12	0	0	0	0	0	0	0.2	0.1	0	0	0.4	0.9	0.4	1.9	0	0	0	0.2	0.2
C60	Penis	4	0	0	0	0	0	0	0	0	0.1	0	0	0	0.4	0	0	6.1	6.2	0.1	0.3
C61	Prostate	140	0	0.3	0	0	0	0	0	0	0	0.2	0.7	2.3	12.4	35.2	66.5	103.8	81	2.1	7.8
C62	Testis	20	0	0	0	0	0	0	0.8	0.8	0.1	0.2	0.1	0.5	0.4	0.9	0	0	0	0.3	0.2
C63	Other Male Genital	1	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0
C64	Kidney	50	0	0.6	0	0	0	0	0.2	0	0.1	0.6	1.5	2.1	3.7	3.7	16.6	0	12.5	0.8	1.4
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C67	Bladder	90	0	0.3	0	0	0	0.4	0.2	0.2	0.2	0.7	1.6	3.8	8.3	10.2	16.6	24.4	49.8	1.4	3.2
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	3	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0	0	0	6.2	0	0.1
C70-C72	Brain, Nervous System	58	0	0.3	0.3	1.3	0	1.3	0.4	0.3	0.2	0.4	1	2.1	5.8	3.7	8.3	6.1	0	0.9	1.3
C73	Thyroid	57	1	0	0	0	0	1.7	1.6	0.5	0.5	0.5	1.5	3.3	0.8	0.9	0	0	6.2	0.9	0.8
C74	Adrenal Gland	1	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C75	Other Endocrine	1	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin Disease	46	0	0	0.6	1.3	2.2	1.7	0.6	0.5	0.3	0.7	0.4	0.7	1.2	2.8	0	6.1	0	0.7	1
C82-C85;C96	Non-Hodgkin Lymphoma	113	0	0.3	0.9	0.7	2.2	0.8	1.8	0.8	0.8	1.3	1.9	3.5	5.4	8.3	13.9	24.4	18.7	1.7	2.9
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	19	0	0	0	0	0	0	0.2	0.1	0.1	0.3	0.3	0.9	1.2	0	2.8	6.1	12.5	0.3	0.6
C91	Lymphoid Leukemia	50	0	3	3	0.3	2.2	2.1	0.8	0.5	0.1	0.2	0.1	0.2	0.4	1.9	0	6.1	6.2	0.8	1.5
C92-C94	Myeloid Leukemia	57	0	0.6	0.6	0	0	1.6	0	0.7	0.3	0.6	0.9	1.2	3.7	4.6	8.3	0	0	0.9	1.1
C95	Leukemia Unspecified	13	0	0	0.3	0.3	0	0.4	0	0	0.1	0.1	0.1	0.5	0.4	0	5.5	12.2	0	0.2	0.6
Other	Other & Unspecified	75	0	0.3	0	0.3	0	0.4	0.2	0.2	0.7	1.2	1.3	5.2	4.1	3.7	5.5	0	18.7	1.1	1.4
All	All Sites Total	1724	2	8	7	5	8	16	14	10	8	15	30	61	112	183	332	446	473	26.1	52.3
Not C44	All Sites but C44	1608	1	8	7	5	8	14	13	9	7	14	28	56	104	169	302	421	448	24.4	48.7

Table 5.4.4 - Age-Specific Rate (ASR), Age-Standardized Incidence Rate (ASR) Among Non-Saudi Females (per 100,000) by Primary Site and Age Groups, 2012

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C01-C02	Tongue	8	0	0	0	0	0	0	0	0.3	0	0	0.9	0	2.3	0	7.2	20.6	18	0.3	1.1
C03-C06	Mouth	4	0	0	0	0	0	0.6	0	0	0	0.4	0	0	0	0	14.4	0	0	0.1	0.5
C07-C08	Salivary Glands	8	0	0	0	0	1.1	0.6	0	0.6	0	0.7	0	1.6	0	0	0	0	0	0.3	0.3
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	8	0	0	0	0	0.5	0	0	0.3	0.2	0.4	1.8	1.6	2.3	0	0	0	0	0.3	0.4
C12-C13	Hypopharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C14	Pharynx Unspecified	10	0	0	0	0	0	0	0	0.3	0	0.4	0.9	4.7	2.3	7.8	0	10.3	0	0.1	0.2
C15	Oesophagus	26	0	0	0	0	0	0	0.4	0.3	0.9	0.4	4.5	1.6	9.1	7.8	21.6	20.6	18	0.4	0.9
C16	Stomach	8	0	0	0	0	0	0	0	0.6	0	0	0.9	0	4.6	7.8	0	10.3	0	0.9	2.6
C17	Small Intestine	80	0	0	0	0	0.5	0	0.9	0.8	1.7	3.5	9.8	25.2	22.8	0	50.3	72	54	0.3	0.8
C18	Colon	37	0	0	0	0	0	0.6	0.9	1.1	0.7	1.4	2.7	7.9	13.7	11.6	28.8	10.3	9	2.9	7.3
C19-C20	Rectum	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.2	0	0	0	3.1
C21	Anus	18	0	0	0	0	0	0	0	0.3	0.5	0	0.9	1.6	9.1	3.9	21.6	10.3	18	0.6	0.2
C22	Liver	11	0	0	0	0	0.5	0	0	0.6	0	0	0	0	4.6	0	0	41.2	18	0.4	1.4
C23-C24	Gallbladder etc.	18	0	0	0	0	0	0	0	0	0.2	0.4	0.9	4.7	6.8	11.6	14.4	30.9	9	0.6	2.3
C25	Pancreas	6	0	0	0	0	0	0	0	0.3	0	0.4	0	1.6	0	3.9	7.2	10.3	0	0.2	0.7
C30-C31	Nose, Sinuses etc.	5	0	0	0	0	0	0	0	0	0.2	0.4	0	0	0	0	14.4	10.3	0	0.2	0.7
C32	Larynx	30	0	0	0	0	0	0	0.4	0	0.7	0.7	4.5	0	13.7	19.4	7.2	51.4	18	1.1	3.3
C33-C34	Trachea, Bronchus, Lung	2	0	0	0	0.4	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0.1	0
C37-C38	Other Thoracic Organs	11	0	0	0.7	1.2	0.5	1.2	0.4	0.3	0.2	0	0	1.6	0	0	0	0	0	0.4	0.4
C40-C41	Bone	4	0	0	0	0	0	0.6	0	0.3	0	0	0	0	0	0	0	0	0	0.1	0.3
C43	Melanoma of Skin	46	0	0	0	0	0	0	0	0.3	0	0	0	9.4	13.7	19.4	35.9	30.9	9	1.7	4.4
C44	Other Skin	2	0	0	0	0	0	0.6	0	0	0	0.4	0	0	0	0	0	0	0	0.1	0.1
C45	Mesothelioma	11	0	0.3	0	0	0	0	0	0	0.2	0.4	0	0	0	0	0	0	0	0.1	0
C46	Kaposi Sarcoma	632	0	0	0	0	0	0	0	0.6	0	0.4	4.5	0	2.3	0	7.2	0	0	0.4	0.7
C47-C49	Connective, Soft Tissue	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0
C50	Breast	632	0	0	0	0.4	0	3.6	7.3	11.3	17.5	38.7	104.4	143.3	154.9	128.1	194.1	226.3	224.9	22.7	44.6
C51	Vulva	2	0	0	0	0	0	0	0	0	0	0	0	0	2.3	0	0	10.3	0	0.1	0.3
C52	Vagina	4	0	0.3	0	0.4	0	0	0	0	0	0	0.9	0	0	0	7.2	0	0	0.1	0.3
C53	Cervix Uteri	57	0	0	0	0	0	0	0.4	0.8	1.9	3.5	8.9	22	9.1	3.9	21.6	20.6	9	2	3.8
C54	Corpus Uteri	55	0	0	0	0	0	0	0.9	0.3	0.7	1.8	4.5	12.6	27.3	19.4	64.7	30.9	18	2	5.9
C55	Uterus Unspecified	4	0	0	0	0	0	0	0	0	0	0	0.9	1.6	0	7.8	0	0	0	0.1	0.4
C56	Ovary	60	0	0	0.3	0.8	0	0.6	2.1	1.4	1.2	3.5	11.6	6.3	15.9	11.6	14.4	0	18	2.2	3.6
C57	Other Female Genital	6	0	0	0	0	0.5	0	0	0	0	0.4	0	1.6	0	11.6	0	0	0	0.2	0.6
C58	Placenta	21	0	0	0	0	0	0.6	0	0.6	0.2	0	3.6	9.4	0	11.6	21.6	0	0	0.1	0.1
C64	Kidney	2	0	0.3	0	0	0	0	0	0	0	0.4	0	0	0	0	7.2	0	0	0.8	1.9
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.2	0	0	0.1	0.2
C66	Ureter	12	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0
C67	Bladder	0	0	0	0	0	0	0	0	0	0	0	0	3.1	0	11.6	21.6	10.3	18	0.4	1.9
C68	Other Urinary Organs	4	0	1.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	31	0	1.4	1.7	0.4	1.1	1.2	1.3	0	0.2	0.7	5.4	3.1	2.3	7.8	0	0	0	0.1	0.2
C70-C72	Brain, Nervous System	110	0	0	0	0.4	1.6	3	6.9	5.2	5	4.2	8.9	15.7	13.7	7.8	7.2	20.6	18	1.1	1.6
C73	Thyroid	2	0	0	0.3	0	0	0	0.4	0	0	0	0	0	0	0	0	0	0	4	5
C74	Adrenal Glands	1	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0	0.1	0.1
C75	Other Endocrine	22	0	0	0.3	0.8	2.1	2.4	1.7	0.3	0.5	0.4	0	1.6	2.3	0	7.2	0	0	0.8	1.1
C81	Hodgkin Disease	60	0	0.7	0.3	0.8	0.5	2.4	0.9	0.8	1.7	1.8	1.8	7.9	18.2	19.4	35.9	30.9	45	2.2	5.3
C82-C85;C96	Non-Hodgkin Lymphoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C88	Immunoproliferative Disease	36	0	0	0	0	0	0.6	0.9	0.3	0	0.7	0	3.1	6.8	7.8	21.6	0	9	0.5	1.6
C90	Multiple Myeloma	32	0	0.7	3.4	0.8	0.5	0	1.7	0.8	0.2	0.7	3.6	3.1	6.8	7.8	0	10.3	18	1.3	1.8
C91	Lymphoid Leukemia	7	0	0	0.3	0	0	0	0	0	0	0	0	3.1	0	0	0	10.3	18	1.2	2.1
C92-C94	Myeloid Leukemia	45	0	1	0.3	0	0	0	1.7	0.8	0.7	1.4	6.2	6.3	13.7	19.4	14.4	30.9	27	0.3	0.5
C95	Leukemia Unspecified	1578	0	12	7	7	11	20	30	29	36	72	202	305	383	369	676	741	612	56.7	120.8
Other	Other & Unspecified	1532	0	12	7	7	11	20	30	29	36	69	193	296	369	349	640	710	603	55.1	116.3
All	All Sites Total																				
Not C44	All Sites but C44																				

Table 5.4.5 Number Of New Cases by Primary Site and Years among Saudi Males, 1994-2012

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
C00	Lip	7	2	5	5	4	2	6	1	5	5	8	6	6	12	9	5	8	8	4
C01-C02	Tongue	32	15	21	24	13	25	29	14	23	29	33	38	38	40	32	42	53	44	42
C03-C06	Mouth	24	23	30	25	24	27	24	27	26	26	38	29	29	39	39	42	45	41	37
C07-C08	Salivary Glands	4	10	6	11	7	12	8	16	14	10	14	15	17	20	17	19	11	14	8
C09	Tonsil	4	9	2	4	6	2	1	4	5	5	2	3	0	4	2	0	2	4	2
C10	Other Oropharynx	2	3	3	1	1	3	0	3	3	0	2	3	0	2	2	1	2	3	4
C11	Nasopharynx	78	59	86	99	109	96	88	121	84	88	101	114	97	93	121	93	131	121	111
C12-C13	Hypopharynx	10	10	18	7	6	6	5	8	6	7	7	10	9	14	5	6	9	9	6
C14	Pharynx Unspecified	0	2	0	0	1	1	0	2	2	4	4	4	3	3	3	2	3	3	1
C15	Oesophagus	77	71	68	60	81	53	67	62	70	68	54	57	58	70	52	69	73	76	83
C16	Stomach	130	129	133	108	122	103	124	126	146	182	150	160	169	169	165	205	165	162	186
C17	Small Intestine	10	8	11	11	15	13	15	13	17	15	22	23	22	28	31	30	27	35	34
C18	Colon	61	87	72	85	104	101	115	120	152	177	202	260	231	270	292	344	303	378	391
C19-C20	Rectum	83	66	66	66	64	89	82	108	123	143	173	192	181	203	195	274	238	279	284
C21	Anus	10	9	7	8	6	5	10	12	14	11	17	16	8	12	12	22	18	11	23
C22	Liver	299	298	276	268	326	296	290	274	292	283	277	289	319	333	338	328	329	330	344
C23-C24	Gallbladder etc.	24	32	25	22	28	25	27	39	41	39	26	37	48	54	54	58	51	73	68
C25	Pancreas	50	49	53	44	60	58	68	53	75	85	82	97	101	128	102	130	114	128	155
C30-C31	Nose, Sinuses etc.	5	6	10	4	10	13	5	9	14	10	10	14	9	10	14	5	9	8	17
C32	Larynx	49	48	43	40	46	43	44	53	32	60	55	51	64	55	61	58	48	70	59
C33-C34	Trachea, Bronchus, Lung	188	183	184	162	223	203	197	189	194	201	253	280	237	325	294	287	292	343	336
C37-C38	Other Thoracic Organs	7	11	12	13	8	17	7	7	5	12	12	22	15	19	11	17	25	21	18
C40-C41	Bone	47	50	34	46	51	53	51	67	51	44	66	56	65	69	78	65	74	71	85
C43	Melanoma of Skin	21	8	8	8	6	7	11	9	12	10	13	14	12	17	13	13	12	16	8
C44	Other Skin	104	117	112	107	97	120	112	154	149	166	140	156	189	168	161	184	168	208	169
C45	Mesothelioma	5	4	5	5	7	2	7	5	3	6	6	9	8	12	18	5	9	12	12
C46	Kaposi Sarcoma	15	10	14	14	12	11	19	19	21	26	26	22	22	18	17	33	21	19	24
C47-C49	Connective, Soft Tissue	85	68	51	60	50	67	55	48	63	69	59	75	64	72	72	72	69	77	86
C50	Breast	11	15	6	12	19	12	15	12	16	16	13	15	17	20	18	24	24	16	25
C60	Penis	3	4	1	8	0	1	1	1	3	1	3	5	1	0	3	2	1	0	3
C61	Prostate	150	148	154	123	159	150	184	170	194	192	247	272	236	259	279	305	280	311	288
C62	Testis	32	21	25	29	38	31	35	35	45	38	46	44	40	63	74	78	78	80	82
C63	Other Male Genital	1	2	0	3	1	2	3	3	3	4	3	2	4	0	0	2	2	6	0
C64	Kidney	69	78	56	63	71	81	73	87	91	84	124	104	120	146	158	185	167	178	190
C65	Renal Pelvis	5	5	0	0	10	2	6	2	1	7	8	4	5	4	5	5	5	3	8
C66	Ureter	1	3	1	0	3	0	4	1	0	6	3	3	1	2	3	1	1	5	2
C67	Bladder	165	154	127	126	152	152	155	143	160	176	175	170	174	173	178	208	193	182	193
C68	Other Urinary Organs	1	1	1	0	1	1	0	0	1	1	1	1	0	1	1	1	3	1	1
C69	Eye	21	12	18	34	16	24	26	22	24	21	21	17	28	23	27	29	22	20	23
C70-C72	Brain, Nervous system	131	99	126	122	101	120	139	120	120	148	155	141	155	139	162	156	148	170	175
C73	Thyroid	73	61	58	73	84	84	77	74	91	87	95	93	121	122	136	150	149	154	193
C74	Adrenal Gland	8	9	8	8	4	9	10	7	6	15	6	10	21	16	16	20	29	13	18
C75	Other Endocrine	2	3	5	1	2	2	1	4	1	5	3	6	5	4	9	6	0	8	9
C81	Hodgkin Disease	104	105	105	97	133	118	125	136	122	145	176	167	178	179	187	199	194	184	194
C82-C85;C96	Non-Hodgkin Lymphoma	272	214	231	226	283	268	265	246	272	329	351	351	363	425	381	436	407	432	424
C88	Immunoproliferative Disease	0	0	0	1	0	1	0	0	0	1	2	0	0	0	0	1	0	1	0
C90	Multiple Myeloma	59	41	30	36	48	37	46	36	30	39	46	60	53	46	40	62	61	50	71
C91	Lymphoid Leukemia	151	118	146	139	150	137	152	158	146	165	155	166	163	195	167	194	187	202	229
C92-C94	Myeloid Leukemia	94	90	84	103	94	109	129	129	115	90	119	109	130	119	144	147	156	148	168
C95	Leukemia Unspecified	10	5	5	5	8	6	14	13	12	14	13	15	26	27	37	16	16	16	21
Other	Other & Unspecified	147	122	98	131	140	138	126	133	153	140	149	179	181	169	155	162	161	169	153
All	All sites Total	2941	2697	2640	2647	3004	2938	3014	3095	3248	3505	3766	3986	4043	4391	4390	4798	4593	4913	5067
Not C44	All sites but C44	2837	2580	2528	2540	2907	2818	2902	2941	3099	3339	3626	3830	3854	4223	4229	4614	4425	4705	4898

Table 5.4.6 Number Of New Cases by Primary Site and Years among Saudi Females, 1994-2012

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
C00	Lip	3	3	4	2	1	5	4	3	6	5	8	6	4	5	6	8	5	7	4
C01-C02	Tongue	21	20	28	28	29	31	23	19	30	30	29	23	25	38	30	39	43	52	51
C03-C06	Mouth	23	38	37	22	32	39	25	27	29	30	21	43	36	51	46	37	48	46	33
C07-C08	Salivary Glands	8	7	6	3	11	8	14	8	6	10	12	13	14	18	17	21	15	22	28
C09	Tonsil	0	3	3	3	1	1	3	1	5	4	1	1	1	3	3	3	0	1	2
C10	Other Oropharynx	0	1	0	0	1	0	0	0	2	0	2	2	0	1	0	0	1	1	3
C11	Nasopharynx	38	27	39	31	37	36	23	41	41	39	45	35	44	56	50	42	40	45	45
C12-C13	Hypopharynx	19	10	14	15	19	16	10	12	12	2	16	16	10	9	17	12	17	16	17
C14	Pharynx Unspecified	2	3	1	1	1	1	2	0	3	1	3	0	1	3	1	3	2	2	2
C15	Oesophagus	75	54	68	52	44	46	55	37	58	50	51	65	62	55	56	47	50	58	63
C16	Stomach	67	71	64	58	66	71	62	72	77	75	76	74	115	126	103	116	126	133	94
C17	Small Intestine	9	11	9	10	16	8	10	14	8	11	13	13	13	14	14	25	13	35	25
C18	Colon	65	80	85	78	72	105	108	143	134	147	179	197	222	246	277	308	306	342	324
C19-C20	Rectum	44	49	52	59	57	86	72	87	104	106	118	144	142	149	163	197	186	195	231
C21	Anus	6	3	1	3	5	2	4	2	5	9	7	8	8	12	7	16	9	15	9
C22	Liver	110	88	101	86	123	93	121	101	116	129	120	114	137	130	126	150	154	158	130
C23-C24	Gallbladder etc.	51	37	25	31	50	59	46	55	41	60	53	68	72	85	83	90	89	90	90
C25	Pancreas	28	30	24	25	50	41	35	35	54	41	35	52	78	53	70	87	81	77	87
C30-C31	Nose, Sinuses etc.	6	9	5	4	9	8	6	5	8	2	6	10	12	13	7	7	4	3	13
C32	Larynx	10	2	7	10	8	10	9	2	7	4	6	6	9	10	5	18	5	6	12
C33-C34	Trachea, Bronchus, Lung	51	55	48	53	50	47	52	57	52	64	69	87	81	91	84	106	105	109	127
C37-C38	Other Thoracic Organs	7	6	5	6	5	5	8	5	3	10	9	11	11	7	12	10	11	7	10
C40-C41	Bone	26	38	38	25	44	37	38	43	35	39	40	41	40	30	49	46	44	58	60
C43	Melanoma of Skin	11	7	7	2	8	8	6	8	7	12	12	9	15	18	11	8	12	15	16
C44	Other Skin	78	55	87	57	83	77	80	102	95	124	131	131	134	119	126	144	151	125	132
C45	Mesothelioma	1	0	1	1	0	4	1	1	3	7	5	6	4	3	2	10	4	1	2
C46	Kaposi Sarcoma	0	3	0	8	7	4	4	5	3	6	5	8	15	6	5	4	6	6	2
C47-C49	Connective,Soft Tissue	42	55	42	46	61	50	48	43	39	54	75	52	41	65	55	66	76	72	59
C50	Breast	429	434	463	464	516	514	602	565	672	713	815	952	988	1173	1215	1353	1473	1590	1542
C51	Vulva	8	6	7	3	3	3	8	7	5	6	11	1	3	4	5	6	9	7	8
C52	Vagina	5	6	2	4	2	3	1	1	5	1	5	7	1	4	0	3	2	4	4
C53	Cervix Uteri	78	73	83	75	94	79	81	84	85	91	89	98	74	102	95	101	82	114	137
C54	Corpus Uteri	57	47	39	48	60	58	92	78	88	111	125	149	151	185	194	257	220	318	315
C55	Uterus Unspecified	3	2	9	10	16	12	5	13	14	15	13	24	24	29	22	31	29	41	48
C56	Ovary	96	100	96	114	107	101	104	111	108	123	119	147	139	147	172	179	175	198	193
C57	Other Female Genital	1	1	0	2	2	4	3	5	4	5	10	6	9	8	6	7	6	12	15
C58	Placenta	17	10	13	7	10	13	8	15	16	5	8	14	22	12	13	12	5	9	3
C64	Kidney	60	37	49	57	52	64	49	70	69	68	84	65	79	84	98	124	117	112	123
C65	Renal Pelvis	0	1	0	2	3	3	2	1	1	2	2	4	4	1	1	3	5	2	0
C66	Ureter	0	1	1	0	1	1	0	1	1	1	2	4	2	0	0	1	4	2	0
C67	Bladder	28	39	23	29	39	37	39	51	41	42	43	39	42	36	40	40	50	52	52
C68	Other Urinary Organs	0	0	0	0	0	1	1	0	0	0	1	1	0	0	1	0	2	0	1
C69	Eye	15	16	18	13	12	24	24	17	20	16	18	20	19	20	17	24	24	19	19
C70-C72	Brain, Nervous System	80	73	76	94	85	78	84	84	85	95	108	103	108	117	95	115	105	99	123
C73	Thyroid	207	218	198	210	264	282	259	258	279	368	346	391	432	459	496	576	548	646	697
C74	Adrenal Gland	10	6	10	11	9	10	14	8	10	14	17	9	10	9	13	11	14	5	17
C75	Other Endocrine	2	1	2	1	2	3	1	0	0	1	2	5	5	4	2	2	1	4	1
C81	Hodgkin Disease	59	69	59	57	74	76	87	78	76	114	105	104	119	135	136	154	142	157	161
C82-C85;C86	Non-Hodgkin Lymphoma	143	149	142	146	186	176	186	202	203	238	244	259	246	285	313	287	296	312	316
C88	Immunoproliferative Disease	0	0	0	1	0	1	1	1	0	1	0	0	0	0	0	1	0	0	1
C90	Multiple Myeloma	20	33	20	13	24	27	25	19	19	16	26	26	33	49	29	39	42	47	52
C91	Lymphoid Leukemia	76	89	80	82	73	95	112	86	101	93	85	86	92	117	118	137	113	142	132
C92-C94	Myeloid Leukemia	77	78	75	90	83	89	93	102	100	103	125	100	122	108	110	127	128	176	171
C95	Leukemia Unspecified	6	6	1	5	6	11	9	4	5	11	11	17	9	19	30	23	16	13	25
Other	Other & Unspecified	103	95	93	95	137	127	122	116	117	161	175	147	170	152	166	164	167	178	140
All	All sites Total	2381	2355	2360	2352	2750	2794	2881	2909	3107	3482	3736	4007	4249	4675	4812	5397	5378	5956	5967
Not C44	All sites but C44	2303	2300	2273	2295	2667	2717	2801	2807	3012	3358	3605	3876	4115	4556	4886	5253	5227	5831	5835


Table 5.4.7 Age Standardized Incidence Rate by Primary Site and Years among Saudi Males, 1994-2012

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
C00	Lip	0.2	0.1	0.1	0.1	0.1	0	0.1	0	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.1
C01-C02	Tongue	0.9	0.5	0.6	0.6	0.3	0.6	0.8	0.3	0.5	0.6	0.8	0.9	0.8	0.8	0.6	0.8	1	0.7	0.6
C03-C06	Mouth	0.7	0.7	0.9	0.6	0.6	0.6	0.5	0.7	0.6	0.6	0.8	0.7	0.7	0.8	0.7	0.8	0.9	0.7	1
C07-C08	Salivary Glands	0.1	0.3	0.2	0.3	0.1	0.2	0.2	0.3	0.3	0.2	0.2	0.2	0.3	0.4	0.3	0.3	0.2	0.2	0
C09	Tonsil	0.1	0.2	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	0.1	0.1	0	0.1	0	0	0	0.1	0.1
C10	Other Oropharynx	0.1	0.1	0.1	0	0	0.1	0	0.1	0.1	0	0	0.1	0	0	0	0	0	0	0
C11	Nasopharynx	2.1	1.5	2.3	2.5	2.6	2.2	2	2.5	1.8	1.7	2	2.2	1.7	1.5	2	1.5	2	1.8	1.7
C12-C13	Hypopharynx	0.3	0.2	0.4	0.2	0.2	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.3	0.1	0.1	0.2	0.2	0
C14	Pharynx Unspecified	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0	0	0	0
C15	Oesophagus	2.2	1.9	1.7	1.5	2	1.2	1.5	1.6	1.6	1.6	1.2	1.3	1.4	1.4	1	1.4	1.4	1.3	1.4
C16	Stomach	3.7	3.6	3.5	2.7	3	2.4	3	2.9	3.2	4.2	3.4	3.5	4.1	3.5	3.2	4	3.1	2.8	1.8
C17	Small Intestine	0.3	0.2	0.3	0.3	0.4	0.3	0.4	0.3	0.4	0.3	0.5	0.5	0.5	0.5	0.6	0.6	0.5	0.6	0.1
C18	Colon	1.8	2.4	1.9	2.1	2.5	2.5	2.9	2.9	3.4	4	4.4	5.8	5.3	5.4	5.4	5.5	5.5	6.6	4.3
C19-C20	Rectum	2.4	1.9	1.6	1.7	1.6	2.3	2	2.4	2.6	3.3	3.9	4.4	4.3	4	3.8	5.1	4.4	4.7	3.5
C21	Anus	0.3	0.2	0.2	0.2	0.2	0.1	0.3	0.3	0.3	0.3	0.4	0.3	0.2	0.2	0.2	0.4	0.3	0.2	0
C22	Liver	8.7	8.6	7.5	7.1	8.4	7.5	7.3	7.1	7.1	7.1	6.6	6.8	8.3	7.2	6.9	6.6	6.4	6.1	6.2
C23-C24	Gallbladder etc.	0.7	0.9	0.7	0.6	0.7	0.6	0.7	1.1	0.9	1	0.6	0.9	1.3	1.1	1	1.1	0.9	1.3	0.7
C25	Pancreas	1.4	1.3	1.5	1.2	1.5	1.4	1.6	1.3	1.7	2	2	2.2	2.6	2.7	2	2.6	2.2	2.3	1.5
C30-C31	Nose, Sinuses etc.	0.1	0.2	0.3	0.1	0.2	0.3	0.1	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.1
C32	Larynx	1.5	1.4	1.2	1	1.2	1.1	1.1	1.5	0.8	1.5	1.3	1.3	1.3	1.6	1.2	1.2	0.9	1.3	0.6
C33-C34	Trachea, Bronchus, Lung	5.6	5.3	4.9	4.4	5.8	5.2	5	4.8	5	5.1	5.9	6.5	6.2	6.9	6	6	5.8	6.4	2.3
C37-C38	Other Thoracic Organs	0.2	0.2	0.2	0.2	0.2	0.3	0.1	0.1	0.1	0.1	0.3	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.5
C40-C41	Bone	0.7	0.7	0.5	0.7	0.7	0.7	0.7	0.8	0.6	0.6	0.7	0.6	0.7	0.7	0.9	0.7	0.7	0.8	1
C43	Melanoma of Skin	0.6	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.2	0.3	0.3	0.3	0.4	0.3	0.2	0.2	0.3	0.1
C44	Other Skin	2.7	3	2.8	2.8	2.4	2.7	2.5	3.5	3.2	3.7	3	3.4	4.5	3.3	3	3.5	3.1	3.6	3.6
C45	Mesothelioma	0.1	0.1	0.2	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.4	0.1	0.2	0.2	0.2
C46	Kaposi Sarcoma	0.5	0.3	0.3	0.3	0.3	0.2	0.4	0.5	0.5	0.6	0.6	0.4	0.5	0.3	0.3	0.6	0.4	0.3	0.8
C47-C49	Connective Soft Tissue	1.8	1.4	1	1.2	0.8	1.2	0.9	0.9	1.1	1.2	0.8	1	1	1	1	0.9	0.8	0.9	0.3
C50	Breast	0.3	0.4	0.1	0.3	0.5	0.3	0.4	0.3	0.4	0.4	0.3	0.3	0.3	0.4	0.3	0.4	0.4	0.3	0
C60	Penis	0.1	0.1	0	0.2	0	0	0	0	0.1	0	0.1	0.1	0	0	0.1	0	0	0	0
C61	Prostate	4	3.9	3.8	2.9	3.9	3.5	4	4.4	4.3	4.5	5.7	6.4	6.3	5.7	5.9	6.3	5.5	6	4.5
C62	Testis	0.7	0.4	0.5	0.5	0.7	0.6	0.6	0.5	0.7	0.5	0.6	0.5	0.5	0.7	0.8	0.8	0.8	0.8	0.3
C63	Other Male Genital	0	0	0	0.1	0	0	0.1	0.1	0.1	0.1	0.1	0	0.1	0	0	0	0	0.1	0
C64	Kidney	1.8	2	1.4	1.5	1.7	1.7	1.7	1.9	1.8	1.8	2.5	2.1	2.7	2.7	2.8	3.2	2.9	2.9	2.1
C65	Renal Pelvis	0.1	0.1	0	0	0.3	0.1	0.1	0	0	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0	0
C66	Ureter	0	0.1	0	0	0.1	0	0.1	0	0	0.2	0.1	0.1	0	0	0.1	0	0	0.1	0
C67	Bladder	4.6	4.3	3.4	3.2	3.8	3.7	3.9	3.4	3.5	4.1	4	3.7	4.2	3.5	3.7	4.1	3.6	3.3	3.8
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0
C69	Eye	0.5	0.2	0.3	0.5	0.2	0.4	0.3	0.5	0.4	0.3	0.4	0.3	0.4	0.3	0.3	0.4	0.3	0.2	0.1
C70-C72	Brain, Nervous System	2.9	1.8	2.4	2.2	1.6	2.1	2.3	2.1	1.9	2.5	2.5	2.2	2.6	2	2.2	2.2	1.9	2.2	1.2
C73	Thyroid	2	1.5	1.5	1.8	1.9	1.7	1.6	1.6	1.9	1.7	1.8	1.6	2.1	1.9	2.1	2.2	2.3	2.2	1.7
C74	Adrenal Gland	0.1	0.1	0.2	0.1	0	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.3	0.2	0.2	0.2	0.3	0.1	0.6
C75	Other Endocrine	0.1	0.1	0.1	0	0	0	0	0	0	0.1	0	0.1	0.1	0	0.1	0.1	0	0.1	0
C81	Hodgkin Disease	2.1	1.9	1.7	1.5	2.2	1.9	1.8	2.1	1.9	2	2.4	2.1	2.1	2.1	2.1	2.4	2.1	1.9	0.7
C82-C85;C96	Non-Hodgkin Lymphoma	6.6	5	5.5	5	6.2	6.1	5.4	5	5.2	6.4	6.2	6.5	6.7	7.1	6.2	7	6.2	6.4	4.8
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	1.8	1.1	0.8	1	1.3	1	1.1	0.9	0.6	0.9	1.1	1.3	1.3	1	0.8	1.2	1.2	0.9	1.2
C91	Lymphoid Leukemia	2.2	1.8	2.1	2.1	2.3	2	2.1	2.4	2.1	2.2	2.1	2	2.5	2.4	2.1	2.4	2.1	2.3	2.4
C92-C94	Myeloid Leukemia	1.9	1.7	1.7	2	2	1.9	1.7	2.1	2	1.5	1.9	1.6	2	1.6	2	2	2	2	1.7
C95	Leukemia Unspecified	0.2	0.1	0.1	0.1	0.2	0.1	0.3	0.3	0.2	0.3	0.2	0.2	0.5	0.4	0.6	0.3	0.2	0.2	0.3
Other	Other & Unspecified	4	3.1	2.6	3.3	3.4	3.4	2.8	3.4	3.5	3.2	3.3	3.9	4.3	3.3	3	3	2.9	2.8	0.8
All	All sites Total	75.9	67.1	63.1	61	68.7	65	65.1	67.9	67.4	73.9	76.3	80	86.6	80.6	77	84	76.7	78.8	58.6
Not C44	All sites but C44	73.1	64.1	60.3	58.3	66.4	62.3	62.7	64.4	64.2	70.2	73.3	76.6	82.1	77.4	74	80.4	73.6	75.2	54.9


Table 5.4.8 Age Standardized Incidence Rate by Primary Site and Years among Saudi Females, 1994-2012

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
C00	Lip	0.1	0.1	0.1	0	0	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1
C01-C02	Tongue	0.7	0.7	0.9	0.8	0.9	0.9	0.6	0.5	0.7	0.7	0.7	0.5	0.6	0.8	0.6	0.7	0.8	0.9	0.8
C03-C06	Mouth	0.7	1.2	1.1	0.7	1	1.1	0.7	0.6	0.7	0.7	0.5	0.9	0.8	1	0.9	0.7	0.8	0.8	0.5
C07-C08	Salivary Glands	0.2	0.2	0.2	0.1	0.3	0.2	0.2	0.2	0.1	0.2	0.1	0.2	0.2	0.3	0.2	0.3	0.2	0.3	0.4
C09	Tonsil	0	0.1	0.1	0.1	0	0	0.1	0	0.1	0.1	0	0	0	0	0.1	0	0	0	0
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0.1	0	0.1	0.1	0	0	0	0	0	0	0
C11	Nasopharynx	0.9	0.6	1	0.7	0.9	0.8	0.4	0.7	0.8	0.7	0.9	0.7	0.8	0.9	0.8	0.7	0.6	0.6	0.6
C12-C13	Hypopharynx	0.6	0.3	0.5	0.5	0.6	0.4	0.3	0.3	0.2	0	0.4	0.4	0.2	0.2	0.3	0.2	0.3	0.3	0.3
C14	Pharynx Unspecified	0	0.1	0	0	0	0	0.1	0	0.1	0	0.1	0	0	0	0	0.1	0	0	0
C15	Oesophagus	2.7	1.8	2.2	1.7	1.4	1.4	1.5	1	1.5	1.2	1.2	1.5	1.6	1.2	1.1	0.9	1	1	1
C16	Stomach	2.4	2.3	2.1	1.7	1.9	2	1.6	1.7	1.8	1.8	1.7	1.7	2.7	2.5	1.9	2.2	2.3	2.3	1.5
C17	Small Intestine	0.3	0.4	0.3	0.3	0.5	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.2	0.6	0.4
C18	Colon	2.3	2.7	2.6	2.3	2.2	2.2	2.6	3.4	3	3.4	4.1	4.2	5.1	4.7	5.3	5.8	5.7	5.3	5.3
C19-C20	Rectum	1.6	1.7	1.6	1.9	1.7	2.2	1.8	2	2.3	2.5	2.6	3.1	3.2	2.9	3.2	3.8	3.4	3.3	3.7
C21	Anus	0.2	0.1	0	0.1	0.2	0	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.2	0.1	0.3	0.2	0.3	0.2
C22	Liver	3.9	3	3.3	2.9	3.8	2.7	3.2	2.7	2.8	3.3	2.9	2.6	3.3	2.8	2.6	3	3.1	2.9	2.3
C23-C24	Gallbladder etc.	1.1	1.1	0.8	0.9	1.6	1.2	0.9	0.9	1.4	1	0.9	1.2	1.9	1.2	1.5	1.8	1.6	1.6	1.6
C25	Pancreas	1.1	1.1	0.8	0.9	1.6	1.2	0.9	0.9	1.4	1	0.9	1.2	1.9	1.2	1.5	1.8	1.6	1.4	1.5
C30-C31	Nose, Sinuses etc.	0.2	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0	0.1	0.2	0.3	0.2	0.1	0.1	0	0.2	0.1
C32	Larynx	0.3	0.1	0.2	0.3	0.2	0.3	0.2	0	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.4	0.1	0.1	0.2
C33-C34	Trachea, Bronchus, Lung	1.9	2	1.5	1.6	1.5	1.4	1.5	1.5	1.2	1.5	1.6	1.9	2	1.9	1.8	2.1	2.1	1.9	2.2
C37-C38	Other Thoracic Organs	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.1
C40-C41	Bone	0.4	0.7	0.7	0.4	0.6	0.5	0.4	0.5	0.4	0.5	0.5	0.4	0.4	0.3	0.6	0.5	0.5	0.6	0.7
C43	Melanoma of Skin	0.3	0.2	0.2	0.1	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.3	0.4	0.2	0.1	0.2	0.2	0.3
C44	Other Skin	2.7	1.7	2.7	1.8	2.4	2.1	2	2.5	2.2	2.9	3.1	2.9	3	2.5	2.4	2.8	2.8	2.2	2.1
C45	Mesothelioma	0	0	0	0	0	0.1	0	0	0.1	0.2	0.1	0.1	0.1	0.1	0	0.2	0.1	0	0
C46	Kaposi Sarcoma	0	0.1	0	0.3	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.4	0.1	0.1	0.1	0.1	0.1	0
C47-C49	Connective Soft tissue	0.9	1.3	1	1	1.1	1	0.8	0.6	0.6	0.8	1.3	0.7	0.6	0.8	0.8	0.8	1.1	0.9	0.7
C50	Breast	13.3	13	13.2	12.5	13.8	12.4	13.5	12	13.9	14.6	16.1	18.4	18.1	20.5	20.3	23.4	24.9	23.4	22.1
C51	Vulva	0.3	0.2	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1
C52	Vagina	0.2	0.2	0	0.2	0	0.1	0	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0	0.1	0	0.1	0.1
C53	Cervix Uteri	2.4	2.2	2.5	2.2	2.8	2	1.9	2	1.8	1.9	1.8	2.1	1.5	1.8	1.7	1.8	1.5	1.7	2.1
C54	Corpus Uteri	2.1	1.4	1.4	1.5	2	1.6	2.5	2	2.2	2.7	3	3.5	3.8	4	4	5.4	4.6	5.8	5.4
C55	Uterus Unspecified	0.1	0.1	0.3	0.3	0.5	0.3	0.1	0.3	0.3	0.4	0.3	0.4	0.6	0.7	0.4	0.6	0.6	0.7	0.8
C56	Ovary	2.9	3	2.7	3.1	3.1	2.3	2.2	2.4	2.2	2.4	2.4	3	2.9	2.6	3.2	3.1	3	3.1	3
C57	Other Female Genital	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.1	0.1	0.1	0.2	0.2
C58	Placenta	0.4	0.2	0.3	0.1	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.3	0.2	0.1	0.1	0.1	0.1	0
C64	Kidney	1.4	1	1.1	1.3	1.4	1.4	0.9	1.4	1.4	1.4	1.8	1.2	1.5	1.4	1.6	2	2	1.7	1.8
C65	Renal Pelvis	0	0	0	0.1	0.1	0.1	0.1	0	0	0.1	0.1	0.1	0.1	0	0	0.1	0.1	0	0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0.1	0	0
C67	Bladder	0.9	1.1	0.7	0.9	1.2	1	1	1.3	1	1	1	0.8	1	0.7	0.8	0.8	1	1	0.9
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	0.3	0.3	0.4	0.2	0.2	0.4	0.4	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.3	0.3	0.2	0.2
C70-C72	Brain, Nervous System	1.4	1.5	1.4	1.9	1.5	1.4	1.5	1.5	1.3	1.6	1.7	1.4	1.7	1.7	1.4	1.7	1.4	1.2	1.5
C73	Thyroid	5.5	5.2	4.7	4.9	5.8	5.6	4.8	4.7	4.8	6.3	5.7	6.2	6.6	6.4	7	8.1	7.5	8.1	8.3
C74	Adrenal Gland	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0	0.2
C75	Other Endocrine	0.1	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0	0	0	0.1	0
C81	Hodgkin Disease	1.4	1.3	1	1.1	1.3	1.2	1.3	1.2	1.1	1.6	1.4	1.3	1.6	1.6	1.6	1.8	1.6	1.7	1.6
C82-C85;C96	Non-Hodgkin Lymphoma	4.2	4.2	4.1	3.9	5	4.1	4.1	4.4	4.4	5	4.8	5.2	5.1	5.1	5.6	5.1	5.2	4.8	4.7
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	0.8	1.2	0.7	0.4	0.7	0.8	0.7	0.5	0.5	0.4	0.6	0.6	0.8	1	0.6	0.8	0.9	0.8	0.9
C91	Lymphoid Leukemia	1	1.6	1.2	1.1	1	1.3	1.7	1.3	1.3	1.2	1.1	1.3	1.3	1.5	1.4	1.6	1.4	1.6	1.4
C92-C94	Myeloid Leukemia	1.7	1.6	1.6	1.6	1.5	1.6	1.7	1.7	1.8	1.7	1.9	1.6	2.2	1.6	1.5	1.8	1.8	2.2	2.1
C95	Leukemia Unspecified	0.1	0.1	0	0.1	0.1	0.3	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.3	0.4	0.4	0.2	0.2	0.3
Other	Other & Unspecified	3.5	3.1	2.8	2.8	4.1	3.3	3.1	3	2.7	3.8	4	3.2	4	3.1	3.3	3.1	3.1	3	2.3
All	All sites Total	70.6	66.9	64.4	62.2	72	65.6	63.4	62.3	64.1	71.2	74.6	77.8	84.4	82.6	82.7	93.1	91.2	90.1	86.7
Not C44	All sites but C44	67.9	65.1	61.7	60.3	69.6	63.6	61.4	59.8	61.9	68.3	71.6	74.9	81.4	80.2	80.3	90.4	88.4	88	84.6


ARABIC SUMMARY



السرطانات العشرة الأكثر شيوعاً بين السعوديين في كلا الجنسين



السرطانات العشرة الأكثر شيوعاً بين البالغين السعوديين في كلا الجنسين



السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين في كلا الجنسين

الملخص العربي

إحصائيات السرطان في المملكة العربية السعودية لعام ٢٠١٢ م

أنشئ السجل السعودي للأورام في عام ١٤١٢ هـ (١٩٩٢ م) بمستشفى الملك فيصل التخصصي ومركز الأبحاث تحت إشراف وزارة الصحة وبمشاركة من القطاعات الصحية الحكومية. يضم السجل خمسة فروع في مناطق المملكة بالإضافة إلى وجود مكاتب في كل من مستشفيات الملك فيصل التخصصي ومركز الأبحاث والقوات المسلحة بالرياض ومدينة الملك عبد العزيز الطبية بجدة وقوى الأمن بالرياض ومستشفى الملك خالد الجامعي بالرياض. بدأ السجل نشاطه في جمع المعلومات من شهر يناير في عام ١٩٩٤ م. تدون المعلومات عن كل حالة سرطان وفق نموذج خاص بالسجل وترمز البيانات وتدخل حسب النظام المعتمد من منظمة الصحة العالمية وتحلل بشكل دوري. كما أن السجل يقوم بتزويد الجهات المختصة والباحثين بمعلومات إحصائية مفصلة بناءً على طلبهم وفق نموذج خاص على صفحة السجل بالموقع الرسمي للمجلس الصحي السعودي:

<http://www.chs.gov.sa/Ar/HealthRecords/CancerRegistry/Pages/CancerRegistryRecords.aspx>

بلغ إجمالي عدد حالات السرطان المسجلة في عام ٢٠١٢ ما مجموعه ١٤.٣٣٦ حالة. من بين هذه الحالات ١١.٠٣٤ سعوديين و ٣.٣٠٢ غير سعوديين بنسبة ٢٣.٠٪ من بين السعوديين ٥٦٧ حالة ذكور بنسبة ٤٥.٩٪ والأناث ٥٩٦٧ حالة و بنسبة ٥٤.١٪.

المجموع الكلي	غير سعوديين			سعوديين		
	المجموع	انثى	ذكر	المجموع	انثى	ذكر
١٤.٣٣٦	٣.٣٠٢	١.٥٧٨	١.٧٢٤	١١.٠٣٤	٥.٩٦٧	٥.٠٦٧

بلغ المعدل العمري المعياري للإصابة بالسرطان بين السعوديين في كل ١٠٠,٠٠٠ من السكان (٧٨.١ بين الذكور و ٨٦.٧ بين الأناث).

السرطانات العشرة الأكثر شيوعاً بين السعوديين في كلا الجنسين :

يحتل سرطان الثدي المرتبة الأولى بعدد (١٥٦٧ حالة) و بنسبة ١٤.٢٪ ثم سرطان القولون والمستقيم (١٢٣٠ حالة) بنسبة ١١.١٪ يليه سرطان الغدة الدرقية (٨٩٠ حالة) و بنسبة ٨.١٪ ثم سرطان إبيضاض الدم (٧٤٦ حالة) بنسبة ٦.٨٪ يليه السرطان اللمفاوي اللاهودجكن (٧٤٠ حالة) بنسبة ٦.٧٪ ثم سرطان الكبد (٤٧٤ حالة) بنسبة ٤.٣٪ ثم سرطان الرئة (٤٦٣ حالة) بنسبة ٤.٢٪ يليه سرطان هودجكن (٣٥٥ حالة) بنسبة ٣.٢٪ ثم سرطان الرحم (٣١٥ حالة) بنسبة ٢.٩٪ وأخيراً سرطان الكلى (٣١٣ حالة) بنسبة ٢.٨٪.

السرطانات العشرة الأكثر شيوعاً بين البالغين السعوديين في كلا الجنسين :

يحتل سرطان الثدي المرتبة الأولى بعدد (١٥٦٧ حالة) و بنسبة ١٥.٢٪ ثم سرطان القولون والمستقيم (١٢٣٠ حالة) بنسبة ١١.٩٪ يليه سرطان الغدة الدرقية (٨٧٩ حالة) و بنسبة ٨.٥٪ ثم السرطان اللمفاوي اللاهودجكن (٦٨٨ حالة) بنسبة ٦.٧٪ يليه سرطان الكبد (٤٦١ حالة) بنسبة ٤.٥٪ ثم سرطان الرئة (٤٦٠ حالة) بنسبة ٤.٥٪ يليه سرطان إبيضاض الدم (٤٥٦ حالة) بنسبة ٤.٤٪ ثم سرطان الرحم (٣١٥ حالة) بنسبة ٣٪ يليه سرطان هودجكن (٣١٠ حالة) بنسبة ٣٪ وأخيراً سرطان الجلد (٢٩٨ حالة) بنسبة ٢.٩٪.

السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين في كلا الجنسين :

يحتل سرطان إبيضاض الدم المرتبة الأولى (٢٩٠ حالة) بنسبة ٤١.٣٪ يليه سرطان المخ والجهاز العصبي (٨٥ حالة) بنسبة ١٢.١٪ ثم السرطان اللمفاوي اللاهودجكن (٥٢ حالة) بنسبة ٧.٤٪ ثم سرطان هودجكن (٤٥ حالة) بنسبة ٦.٤٪ يليه سرطان العظام (٤٤ حالة) بنسبة ٦.٣٪ ثم العين و سرطان الأنسجة الضامة (٣٣ حالة) بنسبة ٤.٧٪ لكل منها ثم يليه سرطان الكلى (٣٢ حالة) بنسبة ٤.٦٪ ثم الغدة الكظرية (٢٢ حالة) بنسبة ٣.١٪ وأخيراً سرطان الكبد (١٣ حالة) بنسبة ١.٨٪.



المملكة العربية السعودية
المجلس الصحي السعودي
السجل السعودي للأورام

تقرير معدل الإصابة بمرض السرطان
٢٠١٢

تتوفر النسخة الإلكترونية على الموقع :

www.chs.gov.sa



المملكة العربية السعودية
المجلس الصحي السعودي
السجل السعودي للأورام

تقرير معدل الإصابة بمرض السرطان ٢٠١٢

حرر في ديسمبر ٢٠١٥ م



Kingdom of Saudi Arabia
Saudi Health Council
Saudi Cancer Registry

Cancer Incidence Report Saudi Arabia 2012

December 2015